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Summary
Gene therapy is a novel approach to the treatment of human disease that is in its very early
stages of development. Its purpose is to add to andlor alter the pattern of gene expression in
cells so as to achieve a therapeutic benefit and is being developed for application to such
diverse conditions as simple inherited diseases, cancer, AIDS, and cardiovascular disease.
Poor uptake of DNA by cells in vivo is a significant technical barrier for gene therapy.
Viruses have evolved to carry their nucleic acid contents into cells very efficiently and are
thus considered as potential vectors for gene therapy, provided their pathogenicity and other
adverse features can be overcome.
Adenovirus is a virus type, which is a prime candidate for development as a vector for
efficient transfer of genes into human tissues. In recent years, there have been many studies
in order to develop replication deficient adenoviral vectors as gene therapy vectors. Current
disadvantages of these vectors include their limited capacity to accommodate exogenous
DNA and elucidation of a host immune response against these vectors. Currently they have
a capacity for about 9 kilobasepairs of DNA, which is not sufficient for some therapeutic
purposes.
The work described in this thesis aimed to provide a way to produce highly deleted
adenoviral vectors containing deletions in their Ll 52155-kD, Ll 52/55-kD and IVaZ' or Ll
52155-kD and IX coding regions. These genes encode proteins, which contribute to virus
particles, and their assembly and some of which have been reported to increase expression
of the viral late (structural protein) genes. Together with the deletions available in currently
used vectors, these new deletions would create vectors with an increased capacity to
accommodate exogenous DNA. Furthermore, these deletions were expected to make the
vectors more replication-deficient and less immunogenic by decreasing the expression of
residual viral genes.
Initially, cell lines expressing adenovirus Ll 52155-kD, Ll 52155-kD and IVaz• or Ll 52155-
kD and IX proteins were constructed for use as complementing cell lines. These were
designed to supply in trans the relevant proteins that would be missing during attempts to
construct recombinant viruses with deletion mutations in these gene(s). 293-Ll cells were
proven in their ability to complement missing Ll 52/55-kD protein function using existing
adenovirus Ll 52155-kD point mutants ts369 and H5pmSOO1. However, attempts to isolate
an Ll 52155-kD coding region deleted recombinant adenovirus using this cell line were
unsuccessful, possibly due to the nature of sequences missing in the deleted Ll 52155-kD
coding region which might have currently undefined cis acting regulatory functions.
Ll 52/55-kD protein is known to form a complex with IVa2 and the latter protein has been
reported to activate the major late promoter. The effects of Ll 52155-kD protein on the
adenovirus major late promoter transactivation were therefore investigated by transient
expression experiments carried out by transfection of COS cells with a major late promoter-
dependant reporter gene (CAT) and expression vectors for Ll 52155-kD andlor IVaz. These
experiments did not reveal any role for the Ll 52155-kD protein in the activation of
adenovirus major late promoter.
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Chapter 1
Introduction
1
1.1 Goals of gene therapy
1.1.1 Introduction
Progress in the study of human disorders over the past 25 years has greatly enhanced
our ability to describe the molecular basis of many disease states. Molecular genetic
techniques have been particularly powerful. They have allowed the isolation of the
genes associated with common inherited diseases such as cystic fibrosis (CF), as
well as the identification of many other genes that contribute to more complex
diseases such as cancers. Because our knowledge of the basic mechanisms
underlying many biological processes such as gene expression and protein synthesis
has also increased, the challenge today is to use all this information in the
development of new treatments for disease.
Gene therapy represents one way in which this knowledge is being applied. Gene
therapy consists of the introduction of nucleic acid into cells of a patient in order to
use the expression of that nucleic acid for some therapeutic purpose. Though simple,
this definition encompasses an extremely wide range of applications such that
defining the goals of all gene therapy applications in more precise terms is difficult.
While the emergence of gene therapy as an accepted clinical practice has occurred
more quickly than many in the field expected, the discoveries that led to the current
gene therapy technology derive from the studies in the early 1970s on RNA and
DNA tumour viruses (Tooze, 1980; Weiss et al., 1985; Freidman and Roblin, 1972).
Investigators probing the mechanisms of transformation by these viruses discovered
that viral genetic material was being transferred to the transformed cell, and this led
to the concept of using a virus as a gene transfer agent. The advent of recombinant
DNA technology in the mid-1970s led to the isolation and manipulation of genes
(Danna and Nathans, 1971; Cohen et al., 1973; Maniatis et al., 1978), and made the
concept of viral vectors a realistic possibility by the end of the decade. The
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development of retroviral-based gene transfer systems in the early 1980s was an
essential contribution, demonstrating that genes could be transferred at high
efficiency both in vitro and in vivo (Shimotohno and Temin, 1981; Cone and
Mulligan, 1984;Miller et al., 1983).
The original ideas of gene therapy were directed toward treating monogenic (single-
gene) disorders, but it has become clear that DNA can be considered a new
pharmaceutical agent for treating many types of diseases. Over the last 20 years, the
initial thoughts of gene therapy have been transformed into reality with more than
175 clinical trials and 2,000 patients already treated (Ross et al., 1996). Yet with all
the trials, there is still no conclusive evidence for efficacy. Although the
expectations have exceeded the initial success of this relatively new field, important
information has been gained from preclinical and clinical trials. With recent
technological advances, gene therapy for treating a wide variety of diseases is likely
to become a reality within the early part of the next century. There are clearly a
number of obstacles limiting successful gene therapy, but the most difficult to
overcome has been the inability to transfer the appropriate gene into a target, non-
germ-cell tissue, such that an appropriate amount of gene product (usually a protein)
is produced to correct the disease.
1.1.2 Methods of gene transfer
The ideal vector for use in gene therapy is at present a theoretical entity, but one
against which current and future vectors can be measured. The ideal vector must
achieve regulated and sustained expression of foreign genes in specific cells or
tissues. This usually requires the foreign genes to be included in constructs that
either integrate within active regions of the genome or that replicate autonomously.
And the whole process must be safe, efficient, and selective. Many problems need to
be solved in developing any gene-therapy approach: definition of the cells that
constitute the target, entry of DNA into those cells, expression of useful levels of
3
gene product over an appropriate time period, avoidance of the almost inevitable
response of the host to the introduced agents, and so on.
The demands made by a gene therapy on its vector are extreme. Vectors have to be
able to access the target cell population, introduce the DNA into the cell in a
transcriptionally active state, be non-toxic (except where the aim is to kill the cells,
such as in cancer therapy) and be able to express the therapeutic gene product at
sufficient levels and for an appropriate length of time to correct the disease
phenotype. Although existing vectors can achieve some of these aims, none can
single handedly provide all the necessary functions (Hodgson, 1995).
There are two approaches that may be utilised for gene therapy - an indirect, ex vivo
method, in which cells are modified in culture and then transplanted, and a direct, in
vivo gene transfer method, involving the injection of a vector. In each case, a
delivery vector must be used and these can be divided into viral and non-viral
systems. In viral methods, a modified virus infects the cells and introduces a viral
genome containing the foreign genes. There are four types of virus vectors currently
in clinical trials - based on retroviruses, adenoviruses, herpes-simplex viruses and
adeno-associated viruses. Non-viral methods, on the other hand, use chemicals
mixed with DNA - such as calcium phosphate coprecipitation, liposomes, and
molecular conjugates - or physical methods - such as electroporation, microinjection
and particle acceleration - to introduce foreign genes into the cell. Although non-
viral gene transfer is safer, compared to viral gene transfer, its major drawback is
that it can only achieve transient expression because there is no effective mechanism
for integration or for autonomous replication, of transfected DNA in human cells.
The main advantage of non-viral methods is that there is no cotransfer of unwanted
viral genetic material to the cell. Additionally, non-viral methods lend themselves
more readily to the standardised manufacturing conditions that are required if gene
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transfer technology is to be applied on a wide scale in medicine (these criteria
include scale up and quality control).
An important property of non-viral gene delivery is that DNA only rarely integrates
into the chromosomes of host cells. Integration has, in fact, never been reported after
non-viral delivery in vivo. Instead, the administered gene is intended to persist as an
extrachromosomal element (episome) capable of expressing gene products for a
discrete period of time before elimination from the host cell by nuclease degradation
(Ledley, 1994). This property of non-viral delivery methods will allow gene
therapies to be used clinically in a manner similar to conventional medicines, which
exhibit a reproducible half-life in the body, leading to a predictable level of the
therapeutic product and duration of action. Non-viral gene therapies are usually
designed to be applicable to both acute and chronic diseases by repetitive
administration, where the dose and schedule of administration can be adjusted to
meet the patient's individual needs.
Viruses have evolved to become highly efficient at nucleic acid delivery to specific
cell types while avoiding immunosurveillance by an infected host. These properties
make viruses attractive gene delivery vehicles, or vectors, for gene therapy. Several
types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV),
and herpes simplex virus, have been modified in the laboratory for use in gene
therapy applications. Because these vector systems have unique advantages and
limitations, each has applications for which it is best suited. Retroviral vectors can
permanently integrate into the genome of the infected cell, but require mitotic cell
division for transduction. Adenoviral vectors can efficiently deliver genes to a wide
variety of dividing and nondividing cell types, but immune elimination of infected
cells often limits gene expression in vivo. Herpes simplex virus can deliver large
amounts of exogenous DNA; however, cytotoxicity and maintenance of transgene
expression remain as obstacles. AAV also infects many nondividing and dividing
5
cell types, but has a limited DNA capacity (Morgan and Anderson, 1993).
1.1.3 Retrovirus-based vector systems
The majority of clinical trials to date have used murine leukaemia virus (MLV)
based retroviral vectors for gene transfer (Miller et al., 1992; Miller, 1992; Guild et
al., 1988). Wild-type MLV encodes three proteins, from the genes gag, pal and env,
which are processed into a number of polypeptides important for replication,
encapsidation, infection and reverse transcription. The three proteins can be
provided in trans, allowing the generation of vectors containing only the cis-acting
elements that are required for these processes (reviewed by Jolly, 1994). Cell lines
that express the three viral proteins stably have been generated, and are termed
packaging lines (reviewed by Miller, 1990). These cell lines can be used to produce
recombinant, replication-defective virus by either stable or transient transfection.
Currently, packaging lines that give titres of greater than 107 infectious virus
particles per ml have been developed (Cosset et al., 1995). The use of different viral-
envelope proteins, such as the G protein from vesicular-stomatitis virus, to produce
pseudotype vectors has improved titres following concentration to greater than 109
ml' (Cosset et al., 1995).
The advantage of retroviruses is that they can stably infect dividing cells introducing
genes into a single, active region of chromatin in each cell, giving a permanency that
facilitates long-term expression by integrating into the host DNA without expressing
any immunogenic viral proteins. In theory the integrated retroviral vector will be
maintained for the life of the host cell, continuing to express the gene of interest. But
a number of problems remain. The most important is the possibility of regenerating
replication-competent retroviruses (RCRs) during initial vector production
(Muenchau et al., 1990). RCRs can generate fatal neoplasms in primates (Donahue
et al., 1992) and, therefore, expensive testing is required for all retroviral vectors
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used in human gene therapy. In addition to this major drawback, retroviral vectors
accommodate only about 8 kb of foreign DNA sequences, they are rapidly
inactivated in vivo by serum complement, they carry a risk of oncogenicity due to
non-specific integration of the genome, transcription of foreign genes is often
inactivated over time, and they can infect only actively dividing cells. However, the
recent development of vectors based on lentiviruses [such as human immuno-
deficiency virus (HIV), simian immunodeficiency virus (SIV) or equine infectious-
anaemia virus (EIAV)], which can infect certain non-dividing cells, should allow the
wider in vivo use of retroviral vectors for gene-therapeutic applications. Indeed,
helper-virus-free stocks of recombinant HIV-based vectors have been generated that
can infect a wide range of non-dividing cells, including neurons, pancreatic islets
and muscle cells (Blomer et al., 1996; Naldini et al., 1996 (a, b).
1.1.4 Adenovirus-based vector systems.
In recent years, the use of adenoviruses (Ads) as gene therapy vectors has received
increasing attention (Bajocchi et al., 1993; Crystal et al., 1994; Davidson et al.,
1993; Perricaudet et al., 1992; Wang and Taylor, 1993; Amalfitano et al., 1999;
Putzer et al., 1997; Leon et al., 1998) due to a number of properties of the
adenovirus system which make it a good candidate for this application, not the least
of which is the extensive understanding of the structure and biology of the
adenoviruses (Shenk, 1996) that has been gained through their use as model system
to study DNA replication, transcription, RNA processing and protein synthesis.
Other advantages include the ease with which the genome can be manipulated by
simple recombinant DNA techniques, the yields of virus that can be obtained in
tissue culture and easily collected and concentrated, and the possibility of high level
expression of foreign DNA inserts. The development of adenovirus-based vectors,
which is the principal subject of this thesis, is discussed in more detail below.
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1.2 Gene therapy using adenoviruses
Adenoviral vectors represent an important class of delivery vehicle for in vivo gene
therapy of diseases where the tissue to be treated cannot be removed, gene-corrected
ex vivo and reimplanted. Cystic fibrosis (CF) provides such an example and has
stimulated evaluation and development of the adenoviral vector system for clinical
use. Several factors account for recent growing interest in adenoviral vectors. First,
they can be easily rendered replication deficient by deletion of critical vital
regulatory genes. Second, they infect a wide range of cell types. Third, they
transduce both dividing and non-dividing cells. Finally, they can be produced easily
and at high titers (1011_1012 infectious units per ml) in laboratory cell culture.
Adenovirus-mediated gene transfer has now been evaluated in various tissues and
organs in animals and in several clinical trials in humans. One specialized role of
adenoviral vectors for gene transfer involves their use as vaccines. Adenoviruses
have also been used in a new type of 'molecular conjugate' gene delivery vector.
1.2.1 General introduction to adenoviruses
The adenoviruses belong to the family Adenoviridae, which is divided into two
genera, Mastadenovirus and Aviadenovirus (Norrby et al., 1976). Adenoviruses
belonging to genus Mastadenovirus infect mammals including humans and the
Aviadenoviruses infect birds. All members of the adenovirus family have similar
chemical and physical properties, but can be distinguished by their individual type-
specific antigens. In man, 47 distinct serotypes (Adl to Ad47) that form six groups
(A to F) have been isolated to date, most of them during the decade following their
discovery (Rowe et al., 1953). Human adenovirus type 5 (AdS), the virus used in
this study, belongs to subgroup C and its genome has been completely sequenced
(Chroboczek et al., 1992).
Host specificity seems to be very stringent in as much as no spread from one host
species to another has ever been reported. An abortive growth cycle usually results
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after infection of cells from another species with human adenovirus. Clinical illness
associated with adenovirus infection depends on the serotype, but is usually mild
and rarely life-threatening. The primary target for adenovirus cytopathology is the
epithelial cell. Productive infections of human adenoviruses take place in
gastrointestinal, respiratory, or ocular epithelial cells, resulting in pathological
alterations mediated by direct tissue damage. For example, some serotypes are
associated with "swimming pool conjunctivitis" (Ad 3, 20) or gastroenteritis (Ad40),
while Ad5 is responsible for mild upper respiratory tract illnesses. The near-
terminally differentiated quiescent cells of the upper respiratory tract lining are the
natural host cells in which Ad5 replicates. From the primary sites of infection the
viral progeny then enter the bloodstream and spread to the other body tissues. The
ultimate outcome of the infection is a chronic and asymptomatic shedding of the
virus in tonsilar, adenoid tissues, guts, or kidneys, depending on the infecting
serotype. Virus can be excreted for months or years following the initial infection
essentially through the oral-fecal and respiratory routes (Evans 1958; Fox et al.,
1969). Ad4 and Ad7 cause more severe respiratory infections which can be as bad as
pneumonia. This, together with the potential for epidemic spread, has led to the
development of a live bivalent vaccine against serotypes 4 and 7 which has been
administered as enteric-coated capsules to United States military recruits (Couch et
al., 1963; Top et al., 1971).
In 1962, it was shown that the human adenovirus type 12 induced malignant tumors
following inoculation into new-born hamsters (Trentin et al., 1962). This was the
first time that a human virus had been shown to cause tumors. However, so far, there
has been no reported evidence that adenoviruses cause malignant diseases in
humans.
1.2.2 Structure and biologyof adenoviruses
Adenoviruses have nonenveloped icosahedral (20 facets and 12 vertices) protein
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capsids with a "diameter" of 70-100 nm enclosing an inner DNA protein core. The
outer capsid is composed of 252 capsomers arranged to form 240 hexons (contacting
6 other capsomers, 12 hexons per facet) and 12 penton bases (contacting 5 other
capsomers); the latter are located at each vertex from which protrude the antenna-
like fibres. This structure is responsible for attachment of adenoviruses to cells.
Adenovirus particles contain 87 % protein, 13 % DNA, no membrane or lipid and
only trace amounts of carbohydrate due to the modification of fiber protein by the
addition of glucosamine; they have a density of 1.34 glcm3 in CsCI (for review, see
Shenk, 1996).
All Adenovirus genomes have the same general organization (genes encoding
specific functions are located at the same position on the viral chromosome). The
double-stranded linear DNA genome of Ad5 is about 36 kb long, conventionally
divided into 100 map units (mu). Each extremity of the viral chromosome has a 100-
140 bp-long redundancy (length varies with serotype), the inverted terminal repeat
(ITR) (Garon et al., 1972; Wolfson and Dressler 1972) which is necessary for viral
replication. Adjacent to the left ITR are located several specific sequences which
direct the packaging of the viral genome into preformed capsids (Hearing et al.,
1987). The requirement for these encapsidation signals makes adenovirus virion
assembly specific and precludes entry of cellular DNA into adenovirus empty
capsids.
By far the most extensively studied adenoviruses are the human serotypes 2, 5, and
12 (for general reviews, see Tooze 1981; Ginsberg 1984). In cultured permissive
cells an adenovirus infectious cycle lasts 30-36 hours beginning with an adsorption
stage followed by an endocytic entry. Attachment of Ad5 to cells is mediated by the
fiber protein binding to its cellular receptor, HeAR (Tomko et al., 1997) an
immunoglobulin-like trans-membrane protein. After attachment, Ad5-HCAR
complexes are internalised by receptor mediated endocytosis, which is triggered by
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the interaction of penton proteins with their cell surface receptors termed integrins
(Wickham et al., 1993). However, the mechanism by which the interaction induces
endocytosis is not clear. The internalised virus moves from the endosome to the
cytosol in a pH-dependent process (Svensson, 1985; Mellman, 1992) by disrupting
the endosomal membrane and the penton base is believed to play an essential role in
the process. Virus particles are then transported across the cytoplasm to the nucleus,
probably by a mechanism involving hexon interaction with microtubules (Dales and
Chardonnet, 1973).
After the internalisation, the virion is dismantled by the sequential elimination of its
structural proteins (Greber et al., 1993) and only its DNase-sensitive genome and
core proteins gain access to the nucleus, allowing the productive cycle per se to
commence. Viral DNA replication can begin only after expression of the early
genes. Shortly after the onset of replication at 6-8 hours post-infection the late phase
of transcription starts. Infection by adenovirus has a profound effect on the host cell
since its DNA and protein productions are halted. Synthesis of viral progeny (1000-
1O,000/cell)leads to cell death through cell lysis (Tollefson et al., 1996).
The genetic organization of the human Ad5 genome is shown in Figure 1.1 where
early and late phase transcription blocks can be distinguished by thin and heavy lines
respectively. By convention, the map is drawn with the El gene at the left end. The
viral chromosome carries five early transcription units (EIA, EIB, E2, E3 and E4),
two delayed early units (IX and IVa2), and one late unit (the major late transcription
unit, MLTU), the transcription from which is processed by alternative splicing to
generate five families of late mRNAs (LI to L5). The two phases of transcription are
temporally separated by the onset of viral DNA replication. The early genes are
initially expressed from those genome template(s) which have reached the host cell
nucleus. Multiple promoters are switched on during the early phase, giving rise to
precursor mRNAs which are alternatively processed extensively. During the late
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phase, other promoters become activated to ensure expression of structural proteins.
However, early genes continue to be expressed at late times after infection and the
promoter controlling expression of the major late transcription unit displays a low
level of transcription early after infection. The viral genes encoding proteins IVa2
and IX begin to be expressed at an intermediate time (Petterson and Roberts, 1986)
and thus form a delayed early category. In addition, the early gene E2A encoding the
DNA binding protein is transcribed from a late promoter after the beginning of viral
replication. Activation of the major late promoter (MLP) at 16 mu gives rise to a
giant nuclear RNA spanning close to 80 % of the genome. This precursor RNA is
processed in a complex fashion into five families (L1 to L5) of mRNAs, each
characterized by the presence of an identical tripartite leader sequence (Figure 1.1).
Within each family the mRNAs also possess the same 3' terminus, defined by a
common polyadenylation signal. Part of the L1 family is also expressed during early
infection. The secondary and/or tertiary structure of the leaders which form the 5'-
terminal segment of all mRNA species issued from the MLP clearly facilitates their
preferential translation (for review, see Horwitz, 1996). Gene expression is
dependent on host cell RNA polymerase II. Adenovirus transcription units tend to
encode proteins with related functions, and splicing contributes to a timely
expression of proteins with similar functions, and regulates the relative proportions
of each.
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The EIA gene is located in the leftmost five percent of the adenovirus genome
(Figure 1.1) and is transcribed from a promoter, which is activated by cellular
factors immediately after infection. It codes for two predominant, related, multi-
functional regulatory proteins. These proteins, by transactivating the transcription of
the other early genes, play a key role in the productive infection (Berk et al., 1979;
Jones and Shenk, 1979; Nevins, 1981). Three other EIA mRNA species accumulate
later during the later stages of the infection, however no definitive unique function
has been described for their products (Shenk, 1996). EIA proteins regulate viral
genes in a complex manner. The larger polypeptide, 289R (translated from the 13S
mRNA), acts either by increasing the DNA-binding activity of transcriptional factors
(E2F, E4F, API, ATF, TATA factor), or by participating directly in the functional
promoter-protein complex through an interaction with a cellular transcription factor.
The transactivating function associated with the smaller polypeptide 243R
(translated from the 12S mRNA), is due to the release of active E2F cellular
transcription factor from pre-existing complexes of E2F with various retinoblastoma
protein family members. The free E2F can then interact with a 19K product of the
E4 gene to generate a new complex able to bind cooperatively to, and transactivate
the viral E2 promoter (for reviews, see Boulanger and Blair, 1991; Nevins, 1991;
Nevins, 1992). Moreover, free E2F, by activating cellular genes including
dihydrofolate reductase, thymidine kinase and DNA polymerase, also contributes to
the establishment of a necessary environment for viral DNA synthesis in otherwise
quiescent cells.
Adenovirus infection induces quiescent cells to enter the S phase of the cell cycle to
create an environment suitable for viral replication, an effect which is primarily
modulated by EIA proteins (Tooze, 1981). EIA proteins interact with a set of
cellular proteins, amongst them pRB (retinoblastoma protein) and p300. pRB
regulates the ability of the E2F cellular transcription factor to activate transcription
and EIA proteins disrupt a series of complexes that contain different pRB family
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members, multiple E2F subunits and cyclins with associated kinases, These
complexes normally regulate cell cycle progression and their disruption by EIA
deregulates normal cell cycle control, allowing quiescent cells to begin DNA
synthesis after infection. EIA proteins also interact with a 300 kD cellular protein
p300, which is a transcriptional co-activator. Adenovirus EIA mutants lacking pRB
binding domains and unable to bind pRB family members can still stimulate cellular
DNA synthesis, provided that the p300 binding site remains intact. Thus, the EIA
proteins contain two independent domains, both of which can stimulate cells to
progress from G1 to S phase of the cell cycle.
EIA proteins of subgroup C adenoviruses also affect the host immune system by
suppressing the anti-viral actions of interferons (IFN) alpha and beta. Another
property of EIA-encoded proteins is to render cells susceptible to cytolysis by NK
cells and activated macrophages (Cook et al., 1987) and TNF (Duerksen-Hughes et
al., 1989). These responses can be detrimental to the survival of adenovirus in an
immune-competent environment. However, on the other hand, EIB and E3 products
have a role in counteracting the susceptibility to TNF cytolysis (for review, see
Wold and Gooding, 1991).
The EIB region found adjacent to EIA (Figure 1.1), codes predominantly for two
unrelated proteins, the 55K and 19K. These proteins seem to have an essential role
in the progression of a productive infection cycle. Like the EIA proteins, EIB-55K
protein also modulates cell cycle progression by targeting the cellular p53 tumor
suppressor protein which, like pRB family members, regulates progression from G1
to S phase. p53 mutations are found in many human tumours since the loss of p53
function by mutation can contribute to tumor progression (Zambetti and Levine,
1993; King and Cidlowski, 1998). p53 is a sequence-specific DNA binding protein
that can activate transcription when it binds to p53-response elements, and it can
repress a variety of genes that lack a binding site for p53 (King and Cidlowski,
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1998). EIB-55K protein antagonises the ability of p53 to influence cell cycle
progression by blocking its activation function (Kao et al., 1990; Yew and Berk,
1992).
EIB-55K also forms a complex with the E4 region-encoded 34K and this complex is
believed to inhibit translation of cellular rnRNAs and to facilitate expression of late
viral genes (Samow et al., 1984). The other EIB protein, 19K, functions
analogously to Bcl-2 to inhibit apoptosis by EIA, p53, and multiple other stimuli,
thus delaying cytopathic effects and premature cell destruction. It also prevents
degradation of viral and cellular DNAs. Finally, the 19K prevents TNF lysis in
human cells (for review, see White, 1998).
The E2 region coded on the left strand is composed of the E2A and E2B units
(Figure 1.1). The various proteins encoded in this region are primarily involved in
replication of the viral genome. The semi-conservative replication begins 6-8 hours
after infection, reaches a maximum rate by 18-20 hours, and it continues until the
host cell dies. The inverted terminal repeats of the viral chromosome contain cis-
acting sequences which serve as replication origins (Challberg and Rawlins, 1984).
A complex of two E2B encoded proteins (preterminal protein and the viral DNA
polymerase) binds to the highly conserved sequence between base pairs 9 to 18
(Temperley and Hay, 1992). The preterminal protein is synthesised as an 80-kd
polypeptide and is found covalently attached to the 5' ends of the viral chromosome.
It is subsequently cleaved by proteolysis during assembly of virions to generate a
55-kd fragment (terminal protein) that remains covalently attached to the genome
(Challberg and Kelly, 1981). The preterminal protein serves as a primer for DNA
replication (Rekosh et al., 1977), preserving the integrity of the viral chromosome's
terminal sequence during multiple rounds of DNA replication. The E2B encoded
DNA polymerase is a 140-kd protein and contains both 5' to 3' polymerase activity
and a 3' to 5' exonuclease activity that serves as a proofreading function during
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DNA synthesis (Field et al., 1984). Chain elongation requires E2 encoded DNA
polymerase and DNA binding protein, and a cellular protein, nuclear factor II (NFII)
which is a topoisomerase.
The virus-coded DNA binding protein (DBP) is a 59 kd phosphoprotein that
migrates in SOS-polyacrylamide gels with an apparent molecular weight of 72 kd
and it binds tightly in a sequence non-specific fashion to single stranded DNA (Van
der Vliet and Levine, 1973). In the presence of DNA binding protein, which coats
single stranded replication intermediates, the polymerase is highly processive (Field
et al., 1984). As well as its replication role, DBP is involved in the host-specific
processing (splicing) of viral fiber mRNAs, and it may also repress viral promoters
(Handa et al., 1983). During the early phase of infection, the E2A promoter at 75.1
mu is the same as that used for E2B; at late times, however, alternative promoters
give rise to the E2A transcript (Nevins and Winkler, 1980).
The E3 region (76.6-86.2 mu) encodes proteins which allow adenovirus infected
cells to evade immunosurveillance. This region is nonessential for viral growth in
tissue culture, but has great importance for the virus in the wild since it has been
found in many adenoviruses studied (Blair and Hall, 1998). The E3 promoter
contains binding sites for the NFkB transcription factor, allowing EIA-independent
transcription of this region in lymphoid cells (Williams et al., 1990). Among the
nine proteins which are potentially encoded by the pre-mRNA which initiates from
the E3 promoter, to date the functions of only four of them can be assigned. The
abundant transmembrane gpl9K is localized in the endoplasmic reticulum where it
associates with MHC class Imolecules and blocks their transport to the cell surface,
thus inhibiting cytotoxic T-lymphocyte recognition of adenovirus-infected cells. It is
noteworthy that gpl9K has a variable affinity for the different human class I
antigens; this implies that the course of adenovirus infections in humans may depend
on both the adenovirus serotype and the MHC genotype of the individual. Three
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other proteins, the 14.7K and the complex 10.4K114.5K act to prevent EIA-induced
TNF cytolysis of human cells, and this occurs even in the absence of the EIB 19K.
The 1O.4K114.5Kcomplex also down-regulates the EGF receptor in adenovirus-
infected cells. Thus, it appears that these three E3 proteins, 14.7K, lO.4K and 14.5K,
interdict signal transduction for TNF and EGF (for reviews, see Wold and Gooding,
1989; 1991; Blair and Hall, 1998).
The E4 region transcribed from right to left (96.8-91.3 mu) (figure 1.1) is essential
for viral growth in cell culture. Its deletion requires that the virus be grown on cells
which complement for the E4 defect (Weinberg and Ketner, 1983). However, frame
shift mutations in six of the seven open reading frames lying within E4 display only
moderate or no effect upon the ability of virus to grow in HeLa cells when studied
individually (Halbert et al., 1985). This makes difficult the attribution of specific
functions to each of the E4 proteins. However, two E4-encoded products were found
to interact with viral and cellular partners: the 19K orf 617protein, which regulates
the transcription of E2 after association with E2F (Hardy and Shenk, 1989; Hardy et
al., 1989; Huang and Hearing, 1989; Neill et al., 1990; Raychaudhuri et al., 1990;
Marton et al., 1990), and a 34K orf 6 protein which has been shown to form a
complex with the 55K EIB protein and play an important role in the expression of
viral late genes (Samow et al., 1984). The E4 proteins are also required for virion
assembly and efficient viral DNA replication (Falgout and Ketner, 1987; Halbert et
al., 1985,'Weinberg and Ketner, 1986; Yoder and Berget, 1986).
Most of the virus-coded proteins synthesised late in infection are virion structural
proteins, or their precursors, required for assembly of the nucleoprotein core and the
outer capsid. Thus, the monomeric structural polypeptides of the hexon (polypeptide
II coded by L3), the penton base (polypeptide III coded by L2), and the fiber
(polypeptide IV coded by L5) assemble in the cytoplasm into capsomers which
constitute the major structural units of the capsid. The penton base and the fiber
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units subsequently combine into the penton. The polypeptides VI and VIII, encoded
respectively by blocks L3 and lA, are found associated with the hexons, whereas the
polypeptide IlIa (coded by Ll) is associated with the peripentonal hexons.
Polypeptide IX, encoded by the transcriptional unit embedded in the EIB region, has
a particular cementing role. It stabilizes the groups-of-nine hexons which form the
central region of each facet of the capsid (Furcinitti et al., 1989). The polypeptides V
and VII encoded by the block L2 are linked to the viral DNA in the core structure.
In addition to the structural proteins of the virion, other non-structural proteins
involved in various assembly steps are also synthesized as late proteins: A lOOK
protein (lA) mediates the assembly of the hexon polypeptide into trimeric units and
thus functions as a scaffolding protein. It is also required for efficient initiation of
translation of viral late mRNA species during the late mRNA species during the late
phase of infection (Hayes et al., 1990). Polypeptide IVa2 is also thought to act as a
scaffold. A 23K protein (L3) displays a sequence specific proteolytic cleavage
activity essential to viral maturation. Several precursor virion polypeptides (pVI,
pVII, pVIII, Illa), as well as the precursor of the terminal protein, are processed by
this endopeptidase during maturation of infectious particles.
All adenovirus serotypes may cause cell transformation following infection of
primary rodent embryo cells in culture, which are non-permissive. The viral genes
responsible for these morphological changes lie within the El region; these genes are
systematically found integrated within the host chromosomes of Ad-transformed
cells with no specificity with respect to the integration site, and they undergo
constitutive expression. The transformation process results, in fact, from the
interaction of the El products with host cell cycle regulatory and apoptosis
regulatory proteins; the EIA proteins interact with the p105 retinoblastoma sus-
ceptibility gene protein (Whyte et al., 1988), while the 55K EIB protein interacts
with the p53 (Samow et al., 1982). Formation of these two complexes is believed to
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release cells from a controlled growth. Finally, the 19K EIB protein (homologous in
sequence and function to the Bcl-2 family of apoptosis regulators) blocks apoptosis
induced by EIA, p53, TNF-a, Fas, and many other apoptotic stimuli (for review, see
White, 1998). EIB 19K protein might also be responsible for the anchorage-
independent growth of Ad-transformed cells by disrupting the vimentin-containing
intermediate filament network (for review, see Boulanger and Blair, 1991).
The oncogenic potential of adenoviruses in animals clearly varies with the serotype.
In addition to their capacity to transform cells in culture, groups A and B adenovirus
(Ad12 and Ad7 are prototypes) also display an oncogenic power in newborn
hamsters. In contrast, group C viruses (e.g., Ad2 or Ad5) are non-oncogenic in vivo.
The molecular basis for the oncogenicity is related to the ability of the EIA gene
products of these serotypes to down-regulate major histocompatibility (MHC) class I
antigen gene expression at the transcriptional level (Bernards et al., 1983; Schrier et
al., 1983).
No association of adenovirus infection with tumors in humans has ever been made.
In fact, in vitro transformation of embryonic cells of human origin is extraordinarily
inefficient with adenovirus. However, the transfection of human embryonic kidney
cells with Ad5 DNA fragments has led to the establishment of a cell line called 293
where 11 % of the left-end of the viral DNA (0-11 mu) is inserted into the cell
genome (Graham et al., 1977; Louis et al., 1997). The availability of these cells is
critical to the generation and propagation of El-deleted recombinant adenoviral
vectors.
1.2.3 Adenoviruses as cloning vectors
The DNA virus used most widely to date for gene transfer vectors is human
adenoviruses (specifically serotypes 2 and 5). Our present understanding of the
molecular genetics of adenovirus renders possible its manipulation as a cloning
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vector for gene transfer both in cell culture and in animals. The most highly valued
advantage of adenoviral-mediated gene therapy is that wild-type adenoviruses are
safe. Millions of North American army recruits have been vaccinated by oral
administration of enteric-coated capsules containing un-attenuated adenovirus and
have rarely displayed adverse side effects (Couch et al., 1963). Furthermore, the
adenoviruses that are modified to make the current lines of vectors (AdS and Ad2)
do not cause tumors in rodents and appear to cause only mild respiratory problems
in humans (Shenk, 1996) and they rarely integrate into host genome, thus they have
little chance to activate a dormant oncogene or interrupt a tumour suppressor gene.
Other suggested advantages are that they are large and can therefore potentially hold
large DNA inserts up to 35 kb; they are human viruses and are able to infect a large
number of different human cell types at a very high efficiency (nearly 100 % in
vitro); they can infect non-dividing as well as dividing cells and they can be
produced at very high titres in tissue culture (as high as 1011pfu/ml).
Adenoviral vectors are made up of at least two components, the modified viral
genome and the virion structure surrounding it. Most present generation vectors
comprise virion particles based largely on the wild type virus structure although
some new approaches have been taken to redirect adenovirus tropism by genetically
or non-covalently incorporating non-native receptor ligands onto the virus coat
proteins (Gall et al., 1996; Krasnykh et al., 1996; Wickham et al., 1995; Michael et
al., 1995; Wickham et al., 1996). This structure packages and protects the viral
nucleic acid and provides the means to bind and enter target cells. In contrast to the
virion structure, the viral nucleic acid in a vector designed for gene therapy is
changed in many ways. The goals of these changes are to disable growth of the virus
in target cells while maintaining its ability to grow in vector form in available helper
cells, to provide space within the viral genome for insertion of exogenous DNA
sequences, and to incorporate new sequences that encode and enable appropriate
expression of the gene of interest. With durable gene transfer as the objective,
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infection of the targeted cells should not lead to cell death (except where the aim is
to kill the cells, such as in cancer gene therapy). Thus, the deletion of key viral genes
constitutes a prerequisite to block the genetic program of the virus.
Adenovirus vector development has focused on crippling the virus by deleting
essential genetic regions and complementing the missing function(s) in trans. Two
general ways for the complementation of the missing function(s) have been
designed. One entails the propagation of replication-defective adenovirus vectors by
the use of a complementing cell line. Complementing cell lines are cells engineered
to express, either inducibly or constituvely, one or more viral gene products. The
second entails the propagation of the recombinant in the presence of a helper
adenovirus for complementation of viral functions lacking in the recombinant.
Recombinant adenoviruses with insertions in place of some viral sequences are
traditionally produced by overlap recombination after cotransfection of appropriate
complementing cells (and/or cells infected with the complementing helper virus)
with a plasmid shuttle vector containing part of the viral genome in which a cassette
for transgene expression has been placed and one or more overlapping viral genomic
DNA fragments, which together comprise a full length genome. The recombinant
viruses generated following this procedure contain the transgene cassette, usually in
place of essential genes, and thus cannot replicate efficiently after the infection of
non-complementing cell lines.
The so-called "first generation" of adenoviral vectors were made by the deletion of
the El region from the viral genome. This deletion rendered the virus replication
defective, so they had to be propagated in cells which had been manipulated to
complement the missing El function in trans. The standard cell line used for this
complementation was the human embryonic kidney cell line 293, (which carries a
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chromosomally integrated segment of AdS DNA from the left end of the genome,
encompassing the El region (Graham et al., 1977) as mentioned above). These
vectors retained the immediate 5' end of the viral genome, including the terminal
repeats, sequences required for packing, and the overlapping El enhancer region.
All coding sequences for EIA were deleted, but often some of the 3' ends of the
EIB gene and all of the protein IX coding sequences were retained since pIX is
indispensable for encapsidation of full-length genome recombinants (Ghosh-
Choudhury et al., 1987). All of the remainder of the viral genome could be left
intact, but usually the sequences encoding the E3 region were also removed in order
to create more space for the insertion of transgenes. The E3 region, as mentioned
earlier, functions to suppress the host immune response during virus infection in
vivo, but is not required for replication or packaging in tissue culture cells. The
icosahedral viral capsid can package viral genomes up to 105 % the length of wild
type viral DNA (Bett et al., 1993); in "first generation" adenoviral vectors with El
and E3 deletions this corresponds to an insertion capacity of about 8 kb of foreign
DNA.
The "first generation" vectors have been shown to be capable of in vivo delivery of
transgenes to a wide variety of both dividing and non-dividing cells, as well as
mediating high levels of transgene expression (Kozarsdy and Wilson, 1993).
However, these vectors elicited strong inflammatory and specific viral immune
responses (Ali et al., 1994) which lead to the elimination of transduced cells by
cytotoxic T cells. Since first generation vectors are deleted in the El region, which
trans-activates the other viral transcription units, it was envisioned that such viruses
would not express the remaining adenovirus genes. However, Engelhardt et al.
(1993) found that low levels of the adenovirus E2A DNA binding protein (DBP)
were expressed in vivo, with high levels detected in a subset of cells showing marker
gene expression. This result indicated that the El deletion was not enough to
preclude expression of other viral genes, an effect observed previously in vitro with
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a high moi of El deleted virus. This is probably a reflection of the fact that, at high
multiplicities of infection, the El region becomes dispensable for replication (Jones
and Shenk, 1979 (b}). This may be related to the expression of specific host gene
products with ElA-like activity (Reichel et al., 1987). This hypothesis is supported
by the fact that it had previously been shown that cellular transcription factors, such
as NF-IL6, could compensate for a lack of ElA (Spergel et al., 1992). Leaky viral
DNA replication is followed by low level viral late protein production.
Accumulation of adenoviral cytotoxic late gene products following gene transfer
causes direct cytopathic effects on the transduced cells (Zhang and Schneider, 1994)
and triggers host cellular immune responses. These adverse effects can be
aggravated by the emergence of El-containing replication-competent adenovirus
(RCA) during the production of El-deleted virus in 293 cells (Lochmuller et al.,
1994). Homologous recombination between the genome of the El-deleted virus and
the adenovirus sequences integrated in the 293 cells has been suggested as the
mechanism for the appearance of the El + RCA in passaged stocks of previously
purified recombinant El-deleted virus. However, a new cell line for
complementation of El was developed by Imler et al. (1996) based on the A549 cell
line (human lung carcinoma cell line). El expression in this cell line was achieved
from a plasmid expression casette. El sequences did not contain the same extended
portion of the viral genome since they lacked the ElB and pIX polyadenylation
signal. Thus the probability of producing RCA through homologous recombination
between the El-deleted virus genome and the existing El sequences in the cells was
eliminated.
Cytotoxicity of viral late proteins and the host cellular immune response against the
adenoviral antigens results in local inflammation and destruction of transduced cells
(Yang et al., 1994 (a.bj), The resulting limited persistence of transgene expression in
vivo observed with "first generation" adenovirus vectors rules out their use in
applications that require long-term expression of transgene products.
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It was hoped that a weaker immune response would result if additional viral genes
were deleted from the vector. Thus, second generation adenoviral vectors have been
designed by the introduction of further mutations into additional adenovirus early
gene regions whose products are required to support and regulate viral DNA
replication which is in turn required for the expression of late genes. Vectors with a
deletion of El coupled with a deletion or inactivating mutation of other essential
early genes, E2b, E2a and/or E4 (Engelhardt et al., 1994; Gao et al., 1996; Gorziglia
et al., 1996; Moorhead et al., 1999), or vectors with all of the viral genes deleted (so
called 'gutless' vectors) (Haecher et al., 1996; Chen et al., 1997) have been
constructed and tested in animals. However, there have been conflicting reports
regarding the immunogenicity of these vectors, and the stability and persistence of
gene expression in vivo from them (Lusky et al., 1998; Goeziglia et al., 1996;
Kaplan et al., 1997; Gao et al., 1996).
In the development of adenoviral vectors, deleting more and more viral genes may
not always be advantageous because some of these genes may have beneficial
features, for example suppressing an immune response against the vector. Their
removal could increase the rate at which the vector is eliminated. As an example. the
E3 region encodes a protein of relative molecular mass 19K that protects the virus
from host immune surveillance. In addition, cis acting sequences may exist that help
maintain the stability of the adenoviral genome in the cell.
There are two other disadvantages associated with the use of adenoviral vectors in
addition to host immune response: first, there is no mechanism whereby these
vectors can persist in dividing cells; second, they have insufficient insert carrying
capacity for some gene therapy applications which require the insertion of relatively
large DNA molecules beyond the capacity of current adenoviral vectors, such as the
full length dystrophin eDNA (14 kb; Koenig et al., 1987). Several attempts have
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been made to increase the capacity of adenovirus vectors for heterologous DNA by
the introduction of further deletions of viral sequences.
A cell line for the complementation of Ad5 protein IX deficiency was developed by
Caravokyri and Leppard (1995), based on the 293 cell line. Since pIX is within the
E1B region and is necessary for packaging full-length genomes (Ghosh-Choudhury,
1987), its deletion from vectors previously placed a restriction on the size of
transgene which could be accomodated. Use of this cell line allowed the
construction of a virus with an increased capacity for insertion of foreign DNA, up
to 9.2 kb in length. Krougliak and Graham (1995) also used 293 cells to express pIX
and coupled this with expression of E4, potentially allowing the generation of
vectors able to accommodate inserts up to 11 kb in length, with deletions in El, E3
andE4.
By engineering the correct combination of viral genes (incorporating
immunosuppressive genes, perhaps from other sources, while deleting immune
stimulating gene products and reducing, if possible, the immunogenicity of viral
capsid proteins), it is likely that adenoviral vectors can be generated that have low
toxicity, that do not generate an immune response, and that, therefore can be given
repeatedly. This would also decrease the requirement for the persistance of the
vector in the host due to the possibility of repeated administration of the vector.
Alternatively, chimeric viral-vector systems that combine advantageous properties
of two or more viral systems could be explored in order to make it possible to
achieve persistance by the incorporation of features in the adenoviral vectors
exploited by other viruses, such as integration into the host genome or autonomous
episomal replication in the host cell nucleus. The insert capacity of the adenoviral
vectors can be increased considerably (up to 35 kb) by the use of so called 'gutless'
adenoviral vectors which contain only the essential adenovirus packing signals and
the origins of replication present at the both end of the genome. Currently these
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vectors are produced in the presence of helper virus but the difficulty of separating
helper virus from the recombinant gutless vector makes this method unsuitable for
producing vectors for use in humans. However, this type of vector might be
generated without the need for a helper virus if a packaging cell line was available
that possessed all the complementing functions required. Though difficult to create,
once such a packaging cell line becomes available, all the viral sequences except the
ones required in cis for replication and packaging may be removed from the vector
genome.
1.3 Adenovirus typeS Ll-S2/SSkD protein and the adenovirus major late
transcription unit (MLTU)
1.3.1 AdSMLTU
Adenovirus late genes begin to be expressed efficiently at the onset of viral DNA
replication. The adenovirus late coding regions are organised into a single large
transcription unit whose primary transcript is about 29000 nucleotides in length
(Evans et al., 1979). This transcript is processed by differential poly(A) site
utilisation and splicing to generate at least 18 distinct mRNAs. These mRNAs have
been grouped into five families, termed Ll to L5, based on the utilisation of
common poly(A) addition sites (figure 1.1) (Chow et al., 1977; Nevins and Darnell,
1978). Expression of this large family of late mRNAs is controlled by the major late
promoter (MLP). This promoter exhibits a low level of activity early after infection.
However, following the onset of viral DNA replication, the rate of transcription
from MLP increases to levels at least 20 times higher than those achieved by the
other viral promoters (Shaw and Ziff, 1980).
Although the promoter for the major late transcription unit (MLP) is active at early
times after the infection, only mRNAs corresponding to the Ll encoding region are
produced (Shaw and Ziff, 1980; Nevins and Wilson, 1981). Full expression of the
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late genes requires viral DNA replication. The major late promoter from adenovirus
types 2 and 5 has been most extensively studied as a model for eukaryotic
transcription (reviewed by Berk, 1986; Logan and Shenk, 1986). Basal transcription
from this promoter depends on a set of well defined promoter elements: a properly
positioned TAT A box, an upstream element (UE) located between positions -67 and
-49 relative to the MLP transcriptional start site, a CAAT box between -80 and -76,
an initiator element spanning the start site, and additional elements located beyond
position +140 (Concino et al., 1984; Hen et al., 1982; LeBowitz et al., 1989; Mason
et al., 1990; Moncollin et al., 1986; Reach et al., 1990; Reach et al., 1991; Zock and
Doerfler, 1990)
Sequence elements located downstream of the MLP start site have been identified
and shown to be essential in vivo for promoter activation (Alonso-Caplen et al.,
1988; Leong et al., 1990; Mansour et al., 1986; Mason et al., 1990). DNase I
protection and dimethyl sulphate interference mapping experiments have delineated
two main downstream sequence elements, DEI and DE2, located between +85 and
+98 (DEl) and + 100 and + 120 (DE2). These elements specifically bind proteins that
are detected only in adenovirus infected cells in the late phase of infection. The
binding of these proteins correlates with the transcriptional activation of the MLP, as
measured by cell-free transcription (Jansen-Durr et al., 1988; Jansen-Durr et al.,
1989) or during infection with recombinant viruses (Leong et al., 1990; Mason et
al., 1990). Footprinting experiments combined with in vitro transcriptional analyses
of selected promoter mutations suggested that the late-phase specific stimulation of
the MLP results from a co-operative action of the UE and DE elements (Mondesert
and Kedinger, 1991).
The presence of two virally induced factors, DEF-A and DEF-B, correlates with late
phase MLP stimulation. DEF-A binds specifically to DEI and also, with lower
affinity, to the 3' portion of the DE2 (DE2a). DEF-B interacts with the 5' part of the
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DE2 element (DE2b). When added together, DEF-A and DEF-B were found to co-
operatively assemble onto the DE2 element as a complex that was more stable than
that formed by each protein alone (Jansen-Durr et al., 1989; Mondesert et al., 1992).
Purification of DEF-B allowed identification of the protein as the product of the
adenovirus IVa2 gene product (pIVa2) and both DNA binding and transcriptional
experiments have confirmed that the IVa2 protein contributes to the late phase-
specific activation of major late promoter (Tribouley et al., 1994; Lutz and
Kedinger, 1996).
1.3.2 Ll·52/55kDprotein
As mentioned earlier, although the major late promoter is active early after infection,
only the 5' proximal Ll family C?fmRNAs accumulates in the cytoplasm at this
time. This finding results from transcriptional termination midway through the
transcription unit and preferential utilisation of the Ll poly(A) addition site
(Iwamoto et al., 1986). The termination is partially relieved as the infection enters
the late phase, allowing expression of full set of mRNAs encoded by the major late
unit.
The Ll family of mRNAs encode three known proteins: the 52- and 55-kilodalton
(52/55-kD) proteins and the IlIa protein. Protein IlIa is a structural component of the
virion (Boudin et al., 1980). The 52/55-kD proteins are phosphoproteins that are
produced as a result of the differential phosphorylation of a 48 kD precursor protein
(Hasson et al., 1992) but they have not been detected in virions (Hasson et al., 1989;
Lucher et al., 1986). Both phosphoforms were shown to be present within all
suspected virus assembly intermediates but not within mature virions (Hasson et al.,
1992). Only Ll 52/55-kD mRNA is produced at early times post-infection.
At late times during adenovirus infection, two abundant particle types are formed
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that can be separated by CsCI equilibrium centrifugation (Maizel et al., 1968). The
heavier of these particles is the mature virus, while the lighter particles are empty
capsids. Proteins that are not found in the mature virions but are found in empty
capsids may function as scaffolding proteins during the assembly process
(Rosenwith et al., 1974). Pulse-chase experiments combined with analyses of
defective particles formed during infection of cells with temperature-sensitive
mutants revealed a third, less-abundant class of particles known as assembly
intermediates (D'Halluin et al., 1978; Edvardsson et al., 1976). Further
characterisation of these particles by reversible cross-linking revealed that they
could be separated into two components, termed heavy and light intermediates.
Light intermediates have the same protein composition as empty capsids but are
associated with a small fragment of the viral genome. The heavy intermediates
contain the full-length viral genome and lack all scaffolding proteins. A
precursor/product relationship between assembly intermediates and mature virions
was suggested by kinetic analyses showing that radiolabel incorporated into
assembly intermediates could be chased into mature virions (D'Halluin et al., 1978;
Edvardsson et al., 1976). A fourth type of particle known as the young virion was
also identified (Ishibashi and Maizel, 1974). Young virions are similar to mature
virions except that several viral proteins are present in a precursor form and some
proteins are absent. Overall these findings suggest that the first step in viral
morphogenesis is association of viral proteins (some in precursor form) with
scaffolding proteins to form the empty capsid. The association of the viral DNA is
the next detectable step and results in the formation of light intermediates. The DNA
is then encapsidated and the scaffolding proteins are degraded or released to produce
heavy intermediates. Young virions are formed by the incorporation of viral core
proteins, and the final step is the cleavage of precursor proteins by the viral protease
to produce the mature virion.
Characterisation of an adenovirus harboring a temperature-sensitive mutation in the
31
L1 52/55-kD protein (ts369) revealed that this protein is required for viral assembly
(Hasson et al., 1989). When HeLa cells were infected with ts369 at the non-
permissive temperature, light intermediates accumulated. Analyses of these
intermediates indicated that they were associated with the left end of the viral
genome, suggesting that the 52/55-kD protein has a role in DNA encapsidation.
Later findings indicated that early assembly intermediates have many copies of the
52/55-kD protein and that these structures gradually lose the 52/55-kD protein as
they mature into virions (Hasson et al., 1992). This led to the suggestion that the
52/55-kD protein may act as a scaffolding protein (Hasson et al., 1992). However,
the analyses of H5ts369 could not differentiate between a role for the 52/55-kD
protein as a scaffolding protein or in DNA encapsidation (Hasson et al., 1992). More
recently it has been shown that the 52/55-kD protein mediates encapsidation of the
viral genome rather than functioning as a scaffolding protein (Gustin and Imperiale,
1998). This indication came by the characterisation of assembly intermediates that
form in the absence of the 52/55-kD protein in cells infected with an adenovirus
mutant incapable of expressing the 52/55-kD protein (Gustin and Imperiale, 1998).
Previously, it was reported that the 52/55-kD protein interacts with the IVa2 protein
during infection (Gustin et al., 1996). Since the IVa2 protein is a late stage specific
transcriptional activator of the major late promoter (Tribouley et al., 1994), this
suggested that a possible additional role for the 52/55-kD protein might be to
regulate proper temporal activation of late gene expression by interacting with the
IVa2 protein. The apparently specific production of the 52/55-kD protein at earlier
times post-infection than other MLTU products agrees with this idea. A potential
role for the IVa2-52/55-kD protein interaction in the regulation of transcription from
the major late promoter is investigated in chapter 7.
1.4 Aims of the project
The main purpose of the work described in this thesis was to increase the capacity of
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the current adenovirus type 5 vectors for the insertion of exogenous DNA to be used
in gene therapy applications. This involved the construction of complementing cell
lines expressing adenovirus type 5 Ll 52/55-kD proteins and/or various other late
proteins to support the production of deleted adenoviral vectors and the deletion of
Ll 52/55-kD coding region from the adenovirus 5 genome. The other purpose of this
work was to investigate the effects of adenovirus Ll 52/55-kD protein on the
activation of adenovirus major late promoter, which is described in a separate
chapter (chapter 7).
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Chapter 2
Material and Methods
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2.1 Materials
A list of commonly used buffers and solutions, and suppliers are presented in
Appendices Band C respectively.
2.2 Bacteriological techniques
2.2.1 Bacterial strains and plasmids and media
A list of bacterial strains and plasmids used in this study and their sources are shown
in Table 2.1 and Table 2.2 respectively. Escherichia coli strains were grown in LB
broth (1 % (w/v) bacto-tryptone, 1 % (w/v) NaCI, 0.5 % yeast extract) at 37°C with
continuous agitation. MI7 (Difco Laboratories) medium supplemented with 0.5 %
(w/v) glucose (GM 17) (Terzhagi and Sandine, 1975) was used for static growth of
Lactococcus Iactis strains at 30°C. Where antibiotic selection of transformed
bacteria was required, transformation mix was plated on LB media containing 1.5 %
(w/v) agar and appropriate antibiotic.
2.2.2 Maintenance of bacterial strains
E. coli strains were streaked on LB agar and L. Iactis strains were streaked on GMI7
agar containing appropriate antibiotics when needed. All bacterial strains were
stored at 4°C and sub-cultured monthly. For long term storage 1 ml of a freshly
saturated culture was added to a freezing vial containing 1 ml DMSO
(dimethylsulfoxide) solution (7 % (v/v» and stored at -70°C.
2.2.3 Rapid preparation of plasmid DNA from E. coli
Rapid plasmid DNA preparation was performed either by using Qiagen's QIAprep
plasmid kit, according to the manufacturer's instructions, or by the following
method (Birnboim, 1989). 1.5 ml of each overnight culture was transferred to a 1.5
ml Eppendorf tube for extraction. Tubes were centrifuged for 15 sec and the
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supernatant was removed. Each pellet was resuspended in 0.1 ml of lysozyme
solution (50 mM glucose, 10 mM EDT A and 25 mM Tris-HCI, pH 8. Lysozyme
was added at a concentration of I mg/ml shortly before use) and held at 0 °C for 5
min. 0.2 ml alkaline SDS (0.2 N NaOH, 1 % (w/v) SDS) at room temperature was
Strain Relevant genotype or phenotype Reference
E. coli
XLIBlue lacZ, recA-, tet' plasmid-free strain Stratagene
XLIBlueMR lacZ, recA- plasmid-free strain Stratagene
MC 1061 recA +, str" plasmid free-strain Wertman, K.F. et
aI, 1986
L. lactis
MG1363 Plasmid-free strain Gasson, 1983
Table 2.1 List of bacterial strains
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Plasmid Relevant genotype Reference
pAdSCla1-
Nhe1
AdS Cla1, Nhe1 fragment (917-10809 bp) This work
cloned in pBR322
pAdSLE-M-1 AdS left end genome (M-1) (1-16746 bp), This work
amp' in pBR322
pAdSLE-M-1- tet' gene cloned in PAdSLE-M-1
tet
This work
pAdSLE-10809 AdS Nhe1 fragment (1-10809 bp) cloned in This work
pBR322
pAdSRE-M-1 AdS right end genome (Llli3) (10294-3S938 This work
bp), kan', amp' in pBR322
pBR322 CoIE1 ori, ROP, amp', tet' Watson, N., 1988
pcDNA3.1IHis PCMV,LacZ, amp', ColE1 ori, SV40 ori, Invitrogen
BflacZ neo'
pCMVSSK PCMV White, E. and
Cipriani, R, 1989
pCMV-CAT CAT gene cloned downstream of PCMV
pCMV-IX AdSpIXcDNA Caravokyri, C. and
Leppard, K., 1995
pCRil amp'jcan'Jacz, Flori, CoIE1 ori Invitrogen
pCR I1-L1 AdS L1-S2/SS kD orf cloned in peR II This work
pFG AdS Sall fragment (Llli3) (16746- 3S938 Caravokyri, C.
bp) (unpublished)
pGEX-2T amp', Plac,gst, colE1 ori Ph armaci a
pGEX-2T-L1 AdS L1-S2/SS kD orf cloned in pGEX-2T This work
pIL2S3 Ery', L lactis ori Simon and Chopin,
1988
pIL2S3-LE AdS left end genome (1-10809 bp) cloned This work
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in pIL253, err
plVa2 Ad5 IVa2eDNA Brey, S., 1999
pMEP4 amp', Ori P, ColEI ori, PhmetIla,SV40 pA, Invitrogen
EBNA-l, hyg'
pMEP-CMV PhmetIIain pMEP4 replaced by PCMVfrom This work
pCMV5SK
pMEP-CMV-
IVa2
Ad5 1Va2 eDNA cloned in pMEP-CMV, Brey, S. 1999
downstream of PCMV
pMEP-CMV-
Ll
Ad5 LI-52/55-kD orf cloned in pMEP- This work
CMV, downstream of PCMV
pMLP-CAT CAT gene cloned downstream of AdS MLP Lutz, et al., 1997
pREP9 Amp', Ori P, ColEl ori, PRSV,SV40 pA, Invitrogen
EBNA-l, neo'
pREP9-lVa2 AdS IVa2cDNA cloned in pREP9 This work
pREP9-IX Ad5 pIX eDNA cloned in pREP9 This work
pSa11C-6Ll Ad5 LI-52/55-kD orf (11050-12158 bp) This work
deleted from pSal1 C
pSal1 C-6Ll-
Kan
kan' gene cloned in pSal1 C This work
pSalIC AdS Sall fragment (9841-16746 bp) cloned Leppard, K.N.
in pBR322 (unpublished)
pXholC Ad5 Xhol fragment (1-5788 bp) cloned in Leppard, K.N.
pBR322 (unpublished)
Table 2.2 List of plasmids
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added and the sample was mixed gently by inversion several times followed by
incubation at 0 QCfor 5 min. 0.15 ml High-salt solution (3 M potassium acetate, 1.8
M formic acid) was added and held at 0 QCfor 15 min after mixing gently, until a
curd-like precipitate was formed. Centrifugation was performed for 2 min and the
supernatant was transferred into another tube. Cold ethanol (0.9 ml) was added to
the sample, which was held at -20 QCfor 15 min, then centrifuged for 1 min. The
pellet was dissolved in 0.1 ml of acetate-MOPS (0.1 M sodium acetate, 0.05 M
MOPS, adjusted to pH 8 with NaOH) and reprecipitated with 0.2 ml ethanol. The
final pellet was suspended in 0.04 ml of dH20.
2.2.4 Rapid preparation of plasmid DNA from L. lactis
The method described by O'Sullivan and Klaenhammer (1993) was used for the
small-scale preparation of lactococcal plasmid DNA. The procedure was devised by
modifying steps from E. coli mini-prep procedures to meet the specific needs of
lactococcal plasmid isolation. 5-10 ml of culture grown overnight in GM17 medium
was harvested by centrifugation at 5000 rpm for 10 min, followed by resuspension
in 25 % sucrose containing 30 mglmllysozyme, to a final volume of 200 J.ll.After
being transferred to Eppendorf tubes, and incubated at 37 QCfor 15 min, 400 J.lIof
alkaline SDS (3 % SDS-0.2 N NaOH) solution was added and incubated for 7 min at
room temperature after mixing. After incubation, 300 J.lIof ice cold 3 M sodium
acetate (pH 4.8) was added, mixed, and centrifuged for 15 min at 4 QCin a bench
centrifuge. The supernatant was transferred to a new tube and 650 J.lIof isopropanol
at room temperature was added, which was then mixed and centrifuged for 15min at
4 QC.The pellet was resuspended in 320 J.lIdH20 and 200 J.lIof 7.5 M ammonium
acetate containing 0.5 mg/ml ethidium bromide, together with 350 J.lI of
phenol/chloroform was added to the suspension. The solution was mixed,
centrifuged for 5 min at room temperature, and the resulting upper phase was
transferred to a new tube. 1 ml of -20 QCethanol was added and centrifuged for 15
min at 4 QCafter mixing thoroughly. Then the pellet was resuspended in 40 J.lIdH20
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or in TE containing 0.1 mg/ml RNase to remove the RNA where needed. The
method is effectively applicable for the isolation of plasmid DNA that has a size up
to 80 kb.
2.2.5 Large scale preparation of plasmid DNA from E. coli
Large scale preparation of plasmid DNA was routinely performed either by Qiagen's
plasmid Maxi kit, according to the manufacturer's instructions or by the following
method (Sambrook et al, 1989). E. coli cells grown overnight in 1000 ml LB
harvested by centrifugation and were resuspended in 25 % sucrose in 50 mM Tris-
HCI and 1 ml lysozyme mix with 2 ml 0.25 M EDTA, pH 8 was added to the
resuspended solution (50 mg/ml lysozyme, 0.25 M Tris-HCI, pH 8). The mixture
was then left for 5 min at room temperature and 8 ml of Triton solution (2 % (vI)
Triton X-WO, 50 mM Tris-HCI pH 8, 62.5 mM EDTA) was added. The tubes
containing the mixture were inverted until the samples became sticky and then
centrifuged at 17000 rpm at 4 "C for 25 min. The supernatant was taken and 1 g of
esC! was added for each ml of supernatant together with 118volume of 5 mg/ml
ethidium bromide. The samples were then centrifuged at 70000 rpm at 10 "C for 4
hours in a Beckman ultracentrifuge. The tubes were observed under ultra-violet light
and the lower band corresponding to plasmid DNA was removed using a syringe and
a needle. Ethidium bromide was removed by extraction 3 times with CsCI-saturated
isoamylalcohol and dialysed overnight against 2 I of TB buffer. The sample was then
transferred to Eppendorf tubes and was stored at -20°C.
2.2.6 Preparation of competent E. coli and transformation with plasmid DNA
A single colony of cells was picked and transferred to 2 ml LB broth and grown
overnight at 37°C. The next day, the 2 ml culture was diluted to 100 ml with fresh
LB and incubation was continued for another 2 hours at 37°C. Then the bacteria
40
were harvested by centrifugation at 5000 rpm for 5 min using Sorvall JA20 rotor and
the supernatant was discarded. The bacterial pellet was resuspended very gently in
50 ml of ice-cold 0.1 M CaCh, kept on ice for 30 min and harvested as before. After
resuspension of the bacterial pellet in 1 ml of ice-cold CaCho cells were transferred
into Eppendorf tubes in 100 I,d aliquots, which were kept on ice. Following the
preparation of competent bacteria, DNA (0.1 J.tg-3 ug) diluted to 100 J.tlwith sterile
dHzO was added to 100 J.tlof competent bacteria, mixed gently and kept on ice for
40 min. The mixture was then heat-shocked in a waterbath at 42°C for 1 min
followed by further incubation on ice for 2 min. To allow the cells to recover from
transformation, 0.8 ml of pre-warmed LB medium was added to the transformation
mixture, incubated at 37°C for 1-2 hours and aliquots (1 %,5 %, 10 %, 20 % of the
1 ml bacterial suspension) were plated out on LB plates containing the appropriate
antibiotic(s). To allow the growth of antibiotic-resistant single colonies, plates were
incubated 15-48 hours at 37°C.
2.2.7 Electroporation of L lactls with plasmid DNA
The protocol of Holo and Nes (1989) was used to prepare electrocompetent cells. To
obtain competent cells, cultures were grown to an optical density at 600 nm of 0.5 to
0,8 and then diluted lOO-fold in SGM17 (GMI7 containing 0.5 M sucrose)
supplemented with 2.5 % glycine to weaken the bacterial cell wall, After growth at
30°C to an optical density at 600 nm of 0.4 to 0.7, the cells were harvested by
centrifugation at 4 °C at 5000 g. Following two washes in ice-cold 0.5 M sucrose
containing 10 % glycerol, the cells were suspended in 1/100 culture volume of this
solution and then stored in 40 ul aliquots at -80°C until use. Before electroporation,
the frozen cell suspensions were thawed on ice. Portions were mixed with 1 ul of
DNA dissolved in dHzO and then transferred to an ice-cold electroporation cuvette
(2 mm-electrode gap) and exposed to a single electrical pulse. A Gene Pulser (Bio-
Rad Laboratories, Richmond, California) delivered the pulse set at 25 J.tF and at 2.5
kV. The cuvette was connected parallel to 200-0 resistor (pulse controller; Bio-
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Rad), resulting in time constants of 4.5 to 5 ms. Immediately following the
discharge, the suspension was mixed with 0.96 ml of ice-cold SOMI7 containing 20
mM MgCI2 and 2 mM CaCI2 (SOMI7MC) and left on ice for about 5 min.
Appropriate dilutions were then made in SOMI7MC, and the cells were incubated at
30°C for 2 hours before 100 ul portions were spread on selective OMI7 plates'
containing appropriate antibiotic. Transformants were enumerated after 2 days of
incubation at 30°C.
2.3 Tissue culture and virus techniques
2.3.1 Mammalian cells and virus strains
A list of mammalian cells and virus strains used in this study and their sources are
shown in Table 2.3.
2.3.2 Maintenance and passage of mammalian cell lines
293, HeLa and COS 1 cell lines were maintained in 90 mm tissue culture dishes
containing 10 ml of medium (other culture vessels used in experiments contained
volumes of medium in proportion to their surface areas). 293 and HeLa cells were
grown in DMEM-IO % NCS, and COSI cells were grown in DMEM-5 % PCS. All
cells were grown at 37°C in a 5 % CO2 humidified atmosphere.
293 cells were passaged at an area ratio of 1:4 or 1:6 and COS I, and HeLa cells
were passaged at a ratio of 1:8 or I: 10 every 3-4 days. All cell monolayers were
washed with versene and passaged with 5: 1 versene/trypsin (0.25 % w/v) solution.
Trypsin was neutralised by the addition of serum equal to the volume of
versene/trypsin used.
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Cell or virus strain Source and/or genotype Reference
293 Human kidney cells expressing AdS Graham et al., 1977
El genes.
293-L1 293 cells expressing AdS L1 52/55- This work
kD protein.
293-L1-IVa2 293 cells expressing AdS L1 52/55- This work
kD and IVa2 proteins.
293-L1-pIX 293 cells expressing AdS L1 52/55- This work
kD and pIX proteins.
COS1 African green monkey kidney cells Gluzman, 1981
expressing SV40 T antigen
HeLa Human cervical epitheloid carcinoma Scherer et al., 1953
Ad5 wt300 Wild-type AdS Jones & Shenk, 1979
(b)
Ad5 ts369 An adenovirus mutant containing a Hasson et al., 1989
temperature sensitive L1 gene
H5pm8001 An adenovirus mutant incapable of Gustin & Imperiale,
expressing the L1 52/5S-kDa protein 1998
Table 2.3 A list of mammalian cells and virus strains
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2.3.3 Freezing and recovery of cell stocks
For long term storage, mammalian cells were frozen in 2 ml freezing vials after
resuspension of the trypsinized monolayer cells from a 90 mm tissue culture dish in
Iml of freezing mixture (92 % serum, 8 % DMSO). Freezing was done slowly at-
70°C for 24 hours by wrapping the freezing vials with a thick layer of tissue paper.
The vials were then transferred to liquid nitrogen storage freezer.
When frozen cells were needed for study, the vials were thawed rapidly in a 37 DC
water bath and the cells were plated at high density onto a 90 mm dish containing 9
ml of prewarmed growth medium. After an incubation of 24 hours the medium was
replaced by 10 ml of fresh growth medium.
2.3.4 Virus infection of cell mono layers
Appropriate dilution of virus stock in 0.5 ml DMEM per plate were added onto 75 %
confluent cells in 90 mm dish after removing the growth medium, and incubated at
37 DCfor 1-1.5 hours with regular (every 15 min) rocking. Then 10 ml of appropriate
growth medium preheated to 37°C was added onto each dish and incubated at the
desired temperature for a desired amount of time. Other culture vessels used in
experiments contained volumes of medium or virus dilution in proportion to their
surface areas.
2.3.5 Harvesting and storage of virus particles from infected cells
Infected cells were harvested when cytopathic effect was visible and lysed by three
freeze-thaw cycles. Cell debris was removed by centrifuging (Beckman OPR
centrifuge, OH 3.7 rotor, 1500 rpm, 3 min) and the supernatant (virus stock) stored
in 2-3 ml aliquots at -70°C.
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2.3.6 Transfection of cell mono layers by the calcium phosphate precipitation
method
The 293 cells from one 90 mm dish were passaged and divided between three 60
mm dishes 24 hours before transfection. Four hours before transfection the medium
was changed to D:MEMIIO % FCS. DNA/calcium phosphate precipitates were
prepared by mixing 50 J,tlof 2x HEPES buffer (16 gil NaCI, 0.74 gil KCI, 2 gil
glucose, 10 gil HEPES), 3 J,tlof 100x phosphate solution (9.9 gil Na2HP04), and
DNA solutions + water to 90 J,tl,then adding 10 I,d of 1.25 M calcium chloride and
blowing air through the solution. The precipitates were allowed to form for 30 min
at room temperature, then the medium was removed from the dishes and the cells
were overlaid with the precipitate suspensions diluted to 5 ml with D:MEM-IO%
FCS. The cells were then incubated for 4 hours at 37°C (5 % C02), with occasional
rocking. The medium was removed from each dish, and I ml of 20 % (v/v) glycerol
in TS buffer was carefully added to each monolayer. This was removed after exactly
Irnin, and the cells were washed twice with TS, then overlaid with DMEM-1O %
NCS. The cells were incubated at 37°C for 12 hours, and the medium was replaced
by fresh medium.
2.3.7 Transfection of cell mono layers by lipofection
When higher efficiency of transfection was required in experiments, a lipofection
method using LIPOFECTACE reagent (GihcoBRL) was performed according to the
instructions supplied by the manufacturer (5 J,tlLIPOFECTACE per 1 J,tgof DNA).
2.3.8 Small scale preparation of adenovirus DNA
Infected 293 cell monolayers in 90 mm dishes were harvested when full cytopathic
became visible (usually in 3-4 days) and cells were pelleted by centrifuging 5 min at
1500 rpm in a Beckman GPR centrifuge (GH 3.7 rotor). The supernatant was
removed and the pellet was resuspended in 0.4 ml of TE (pH 9)/10 mM spermine
tetrahydrochloride (Sigma). The suspension was mixed with 0.4 ml DOC lysis
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buffer (20 % (v/v) ethanol, 100 mM Tris-HC1 pH 9, 0.4 % (w/v) sodium
deoxycholate) and cell debris was pelleted by centrifugation (15 min, 12000 rpm,
microcentrifuge). The supernatant was collected and 60 J..LI10 % (w/v) SDS, 40 J..LI
0.25 M EDTA, and 20 J..LIof 20 mg/ml proteinase K (Boehringer) were added. The
solution was mixed several times by inversion and incubated at 37°C for 1 hr.
Residual protein was then extracted with phenol/chloroform and the DNA
precipitated by adding 30 J..LI5 M NaCl and 0.6 ml of propan-2-o1 at room
temperature. The solution was mixed several times by inversion and the DNA was
pelleted by centrifuging for 15 min at 12000 rpm in a microcentrifuge (room
temperature). The DNA pellet was dried and resuspended in 50 J..LIdistilled water.
2.3.9 Large scale preparation of adenovirus DNA
Infected Hela or 293 cells from ten 90 mm dishes were harvested as described above
resuspended in 10 ml of 0.1 M Tris-HC1 (pH 8). The infected cell suspension was
disrupted by sonication on ice (two sets of 10 x Is pulses separated by 30 sec using a
Jencons GE375 ultrasonic processor and 3 mm tapered microtip) and transferred to a
30 ml Corex tube to be clarified by centrifugation (6000 rpm for 10 min, 4°C, in a
Beckman J2-21M centrifuge with JS-13.1 rotor). The supernatant was collected and
5 ml fractions were layered over CsCI step gradients consisting of 2 ml of CsCI in
TD (density 1.40 g/ml) with an overlay of 3 ml of CsCl in TD (density 1.25 glml).
The gradients were centrifuged at 35000 rpm for 1 hour (15 QC)in a Beckman L8-
70M ultracentrifuge (SW 41 rotor). The virus formed a clearly visible band below
cellular debris, which was recovered by puncturing the bottom of the tube and
collecting drip fractions. Collected virus from all the tubes was then pooled and
centrifuged to equilibrium (at least 15 hr) in CsCIffD of density 1.35 g/ml at 40000
rpm (15°C, Beckman L8-70M ultracentrifuge, SW 50.1 rotor). The virus band was
collected (as above), diluted with two volumes of water and precipitated with six
band volumes of ethanol at -70°C for 15 min. Centrifuging for 20 min at 7000 rpm
(4°C) in a Beckman J2-21M centrifuge (JS-I3.1 rotor) pelleted the virus. The pellet
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was dried and gently resuspended in 2 ml of TNE, then 120 J.1110 % (w/v) SDS, 40
J.110.25 M EDTA and 20 ul 10 mg/ml proteinase K were added. The solution was
incubated at 37°C for 1-2 hours then extracted with 2 ml of phenollTNE at room
temperature. The tube was gently swirled for 1 min, 1 ml chloroform/amyl alcohol
was added, and the solution was again gently swirled to mix. Phases were separated
by centrifuging for 10 min at 3000 rpm (4°C) in a Beckman GPR centrifuge, and
the organic extraction and centrifugation were repeated with the aqueous phase.
DNA was precipitated from the final aqueous phase by adding sodium acetate
solution to 0.3 M and two volumes of ethanol. The DNA was allowed to precipitate
at -70°C for 30 min, and then pelleted at 7000 rpm for 30 min (4°C) in a Beckman
J2-21M centrifuge (1S-13.1 rotor). The DNA pellet was washed with 70 % ethanol,
dried, and allowed to redissolve in 0.5 ml TE at 4 QCovernight.
2.3.10 Determination of virus stock titers by plaque assay
Serial dilutions of virus stocks were prepared in DMEM in the range of 10-1 - 10-9
and aliquots of the dilutions were used to infect duplicate cultures of cells in 6 well
tissue culture dishes. Immediately after infection, cells were overlaid with semi-solid
medium (4 % (v/v) NCS, 0.375 % (w/v) NaHC03, 1 % (w/v) noble agar, in
DMEM). After an incubation period of 3-4 days, a second overlay (1 % (v/v) NCS,
0.188 % (w/v) NaHC03, 1 % (w/v) noble agar, in DMEM) was added. When the
plaques became visible (usually within 4-6 days), they were stained by the addition
of an overlay containing neutral red (1 % (v/v) NCS, 0.188 % (w/v) NaHC03, 1 %
(w/v) noble agar, 0.01 % (w/v) neutral red, in DMEM) and counted the next day.
2.4 DNA manipulation techniques
2.4.1 Digestion of DNA with restriction enzymes
Restriction enzymes were purchased either from Gibco BRL or New England
Biolabs and the digestions were carried according to the manufacturer's instructions,
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using concentrated buffers supplied with the enzyme. Multiple enzyme digests were
carried in the same reaction tube provided that their buffers were compatible.
Otherwise the reactions were carried out sequentially, DNA being purified between
each reaction.
2.4.2 End-fill and overhang removal reactions
To produce blunt end termini of DNA fragments for cloning by blunt end ligation,
T4 DNA polymerase (Gibco BRL) was used with all four dNTPs according to the
manufacturer's instructions. The DNA was then purified by phenol/chloroform
extraction as explained in section 2.4.3.
T4 DNA polymerase produces blunt ends by removing 3' protruding ends because
of its strong 3' to 5' exonuclease activity. Similarly if the termini have 5' protruding
region, the enzyme will simply extend the recessed 3' termini due to its polymerase
activity.
2.4.3 Dephosphorylation of DNA
In order to prevent self-ligation of vector DNA termini in cloning experiments,S'
termini of vector DNA were dephosphorylated by using calf intestinal phosphatase
(CIP) (Boehringer). 5 f.11of phosphatase buffer (supplied by the manufacturer), 14 f.11
dH20 and 7 units of ClAP was added to 30 f.11of reaction mixture containing 1.5 f.1g
plasmid DNA digested with restriction endonuclease(s). The reaction was carried
out at 37°C for 15 min and the ClAP was inactivated by further incubation at 75 °c
for 15min. DNA was then purified by phenol/chloroform extraction.
2.4.4 DNA ligation reactions
In order to join duplex DNA restriction fragments having either blunt ends or
compatible cohesive ends for cloning purposes, T4 DNA ligase (Gibco BRL) was
used according to the manufacturer's instructions. For blunt end ligation, reactions
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were carried out at room temperature and cohesive end ligation reactions were
carried out at 15°C. Both kinds of reactions were incubated overnight.
2.5 Separation and purification of DNA fragments
2.5.1 Agarose gel electrophoresis
Agarose gels were cast by melting the agarose in 50 ml of TBE buffer in a ratio of
0.5-1.5 % (w/v) until a clear transparent solution was achieved. 2 J.11of ethidium
bromide (10 mg/ml) was added to the melted solution and then poured into a
horizontal gel apparatus and allowed to harden. The gel was submerged in TBE
buffer and samples, which were mixed with the gel loading buffer, were applied in
the wells formed by the removal of the comb after the gel was hardened. An electric
field of 8 volts/em was applied until the bromophenol blue dye, present in the gel
loading buffer, reached the 2/3 length of the gel. The gel was removed and the DNA
fragments were visualised under ultraviolet light.
2.5.2 Purification of DNA fragments from agarose gels
After visualisation of the DNA fragments following separation by agarose gel
electrophoresis, the required fragments were cut out of the gel by using a scalpel and
placed in dialysis tubing filled with TBE buffer. The tubing was sealed at both ends
by clippers and the DNA was electro-eluted into the TBE buffer present in the
dialysis tube in a gel tank containing TBE buffer. The eluted DNA was then
transferred into a microfuge tube and extracted with phenol/chloroform.
Alternatively, for the purification of DNA fragments in the size range of 500-10000
bp, the DNA extraction kit from Qiagen was used according to the instructions
supplied by the manufacturer.
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2.5.3 Phenol/chloroform extraction and ethanol precipitation of DNA
An equal volume of phenol/chloroform/isoamyl alcohol (25:24: 1) was added to the
DNA solution to be purified in a 1.5 or 2 ml microcentrifuge tube and mixed by
vortexing, followed by centrifugation at 15000 rpm in a microcentrifuge for 1 min.
The resulting aqueous layer was transferred to a fresh tube (extraction was
sometimes repeated several times to achieve improved purification) and the DNA
was recovered by the following ethanol precipitation method.
In order to recover DNA from solutions, precipitation of DNA by ethanol was
carried out by adding 0.1 volumes of 3 M sodium acetate, pH 5.2, and 2 volumes of
cold ethanol (at -20°C) followed by incubation at -70°C for 30 min. The mixture
was then centrifuged for 10 min at 1500 rpm in a microcentrifuge and the pellet was
dried and resuspended in desired volume of dH20.
2.5.4 Spectrophotometric quantification of DNA
DNA in a solution was quantified by taking absorbance readings at 260 nm in a
spectrophotometer. An absorbance of 1 corresponds to 50 ug/ml of double stranded
DNA and 20 ug/ml of single stranded DNA oligonucleotide. Absorbance readings of
the samples were also taken at 280 nm and the ratio A26o-A28owas used to assess the
purity of the solutions. Ratios lower than 1.6-1.8 indicate contamination of the
solution with other molecules and prevents accurate quantification by this method.
2.6 Polymerase Chain Reaction (PCR)
2.6.1 Primers
Designed primers were ordered from Gibco BRL. The sequences of the primers used
are given in Appendix A.
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2.6.2 peR amplification reactions
Appropriate primers were used to amplify predetermined regions of a template DNA
in a 50 J.tlvolume of PCR mixture (10 mM Tris-HCI pH 8.3, 50 mM KCI, 0.01 %
gelatine, 0.2 mM of each dNTP, 0.1 % Triton-X100 and 0.25-3 mM MgCh
(concentrations differ for specific PCR» containing 1 J.tM of each primer and 0.4
units of Taq DNA polymerase, overlaid with 80 J.tl of liquid paraffin. Standard
reaction conditions were 25-30 cycles of 1 min denaturation at 92°C, 1 min
annealing at an appropriate temperature for the choosen oligonucleotides (42 °C-60
QC) and 3 min elongation at 72°C. Actual conditions were optimised for each
primer-template combination. 15 J.tl of the resulting PCR reaction mixture was
analysed by agarose gel electrophoresis. As required, the PCR products were
purified by using Qiagen's DNA purification from PCR kit, as recommended by the
manufacturer.
2.6.3 Detection of recombinant plasmids in bacterial colonies by PCR
Cells from a colony were inoculated (as DNA source) using a sterile toothpick
directly into a 50 III PCR mixture and PCR was performed as described in section
2.5.2.
2.6.4 Detection of Adenovirus recombinants by PCR
a) from cultured cells overlaid with liquid medium
Cells in a 60 mm dish were collected after trypsinisation and pelleted (Beckman
GPR centrifuge, GH 3.7 rotor, at 1500 rpm for 3 min). After resuspension in 400 J.tl
of NP40 lysis buffer, cells were incubated on ice for 10 min and pelleted as before.
The resulting supernatant containing any viral particles were transferred to a clean
microfuge tube and incubated at 37°C for 4 hours with 0.5 mg/ml proteinase K and
0.5 % SDS (for 500 J.LI of supernatant 27 J.tlof 10 mg/ml proteinase K and 27 J.tlof
10 % SDS) to degrade viral coat proteins. Viral DNA was then recovered by three
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times phenol/chloroform extraction, ethanol precipitation and resuspension in 50 J..t.l
of dH20. 5 J..t.lof this suspension was used in PCR amplification reactions for
detection as described in section 2.5.2.
b) from cultured cells overlaid with agar medium
Identified virus plaques were taken off the tissue culture plate using a Pasteur pipette
and resuspended in 1 ml of DMEM-lO %FCS. 370 ul of the suspension was taken
and added to 40 J..t.lof lOx DNase I buffer (400 mM Tris-HCI pH 7.5, 60 mM
MgCh) and 10 units of DNase I (Boehringer) for 1 hour at 37°C. Then, DNase I and
viral capsid proteins were denatured by the addition of 32 ul of 0.25 M EDTA, 0.25
M EGTA, 10 J..t.lof 20 % SDS, 5 J..t.lof 16 mg/ml proteinase K and incubation for 2
hours at 56 GC. DNA was recovered by phenol/chloroform extraction, ethanol
precipitation and resuspension in 20 ul of dH20. 5 ul of this suspension was used for
PCR amplification.
2.7 DNA sequencing
2.7.1 Construction of nested deletions of cloned DNA for use in DNA
sequencing
10 ug of plasmid containing the cloned DNA to be sequenced was completely
digested with restriction enzymes that left a 3' overhang adjacent to the primer
binding site and a 5' overhang or blunt end adjacent to the insert DNA (see Figure
7.2.1). The 5' or blunt restriction site was positioned between the 3' restriction site
and the insert and complete digestion was verified running a small aliquot on an
agarose minigel. DNA was recovered by phenol/chloroform extraction, ethanol
precipitation and dissolved in Ix exo III buffer (15 mM Tris-HCI, pH 8.0 and 0.66
mMMgCh) for a final concentration of 0.1 J..t.g/J..t.l.25 ul of the solution was taken to
a new tube and 150 units of exo III per pmol susceptible 3' ends was added. At 1
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min intervals, 3 III aliquots were removed to individual tubes and placed
immediately on dry ice for 5 min. 3 III of dH20 was added to each sample and
incubated for 10 min at 70 QCto inactivate exo III.
To create blunt ends on the exo III-treated DNA by removing single stranded
portions, 4 III (4 units) of SI nuclease together with 15 III SI nuclease buffer (16
mM sodium acetate, pH 4.6, 400 mM NaCI, 1.6 mM ZnS04, 8 % glycerol) was
added to each aliquot and incubated 20 min at room temperature. SI nuclease
reaction was stopped (via pH shift) by adding 5 III SI nuclease stop buffer (0.8 M
Tris-HCI, pH 8.0, 20 mM EDTA, pH 8.0, 80 mM MgCh) to each sample. The extent
of deletion in each sample was examined by running 8 III of each sample on agarose
gel electrophoresis. Then, 1 III (2 units) DNA polymerase Klenow fragment with
0.25 mM dNTP mix was added to the remaining 22 III of each sample and incubated
at 37 QCfor 10 min to fill in any recessed 3' ends.
DNA in each sample was purified by phenol/chloroform extraction, ethanol
precipitation and resuspension in 29 III dH20, and then recircularizied by the
addition of 6 III (6 units) T4 DNA ligase, 0.5 III 0.1 M ATP, 4 III lOx ligase buffer
(500 mM Tris-HCI, pH 7.5, 70 mM MgCh, 10 mM DTT) and incubation overnight
at room temperature.
Competent E.coli cells were transformed with 10 III ligation reaction from each
sample. One clone from each transformation was analysed by restriction analysis
after plasmid isolation and linearization by a suitable restriction enzyme and
plasmids showing the desired extents of deletions were saved for DNA sequencing.
2.7.2 DNA sequencing by dideoxy method
Sequencing reactions were carried out by using the Sequenase (Version 2.0) kit from
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United States Biochemical Corporation according to the instructions provided with
the kit and 35S_dATP (Amersham).
2.7.3 Denaturing polyacrylamide gel electrophoresis for DNA sequencing
reactions
Denaturing polyacrylamide gels were cast by the polymerisation of
acrylamide:bisacrylamide in the presence of urea. For this, 3.42 g acrylamide, 0.18 g
bisacrylamide, 26.4 g urea were dissolved in freshly prepared 25 ml TBE buffer and
the volume was made up to 60 ml by using TBE. This acrylamide solution was
filtered to remove any impurities and to this filtrate 240 J.tl 10 % ammonium
persulfate (APS) and 24 J.tlTEMED was added to start the polymerisation process.
Immediately after mixing, the solution was poured into vertical sequencing gel
apparatus (BioRAD) and the top of the apparatus was sealed by the placement of a
shark's tooth comb. After the samples were loaded into the wells, the electrophoresis
was run at 2000 volts until the bromophenol dye reached the end of the gel. The gel
was then soaked for at least 20 min in 5 % acetic acid, 15 % methanol to remove the
urea and dried at 80 QC for 2 hours under vacuum. The bands were visualised by
autoradiography (section 2.9.4).
2.8 Analysis of Proteins
2.8.1 Spectrophotometric determination of protein concentration
The protein concentration of sample solutions was determined using the BioRAD
protein assay kit (according to the manufacturer's microassay procedure) and a
spectrophotometer.
2.8.2 Separation of proteins by SDS polyacrylamide gel electrophoresis
Discontinuous SOS-polyacrylamide gels (Laemmli, 1970) were prepared and run in
a Gibco BRL vertical gel electrophoresis apparatus according to description of
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Sambrook et al. (1989). Protein samples were heated to 95 QCfor 3 min in loading
buffer (100 mM DIT, 25 mM Tris-HCI pH 6.8, 10 % glycerol, 2 % SDS and 0.005
% bromophenol blue) just before applying to the gel. After performing
electrophoresis until the blue dye reached the bottom of the gel, it was either fixed
by soaking in 25 % methanol, 7 % glacial acetic acid for at least 30 min and dried at
70 QCfor 2 hours for the detection of radiolabelled samples by autoradiography
(section 2.9.4) or stained by soaking the gel in at least 5 volumes of staining solution
(0.25 g of Coomassie Brilliant Blue R250 in 90 ml of methanol.Hso (1:1 v/v) and
10 ml of glacial acetic acid) for 4 hours at room temperature. The gel was destained
by soaking it in methanol/acetic acid solution (as before) without the dye on a
slowly rocking platform for 4-8 hours changing the solution 3 or 4 times and stored
in water in a sealed plastic bag.
2.8.3 Transferring proteins from acrylamide gels to nitro-cellulose membrane
When the SDS polyacrylamide gel was approaching the end of its run, the gel was
removed and transferred to a tray of water and then placed in contact with a piece of
prewetted nitro-cellulose filter (Hybond-C, Amersham) which was cut at the same
size as the gel. The gel and filter were then sandwiched between Whatman 3MM
paper, two porous pads and two plastic supports, all prewetted in transfer buffer (39
mM glycine, 48 mM Tris base, 0.037 % SDS, 20 % methanol, pH 8.3). The entire
construction was then immersed in an electrophoresis tank equipped with standard
platinum electrodes, which contained transfer buffer. The nitro-cellulose filter was
placed toward the anode (Figure 2.2) and an electric current of 70 volts was applied
for 2 hours to transfer the proteins on to the nitro-cellulose filter.
2.8.4 Detection of proteins by Western Blotting
After the transfer of proteins to the nitro-cellulose filter, any remaining protein
binding sites on the were blocked by incubation in 5 % (w/v) non-fat dried milk in
PBS for 1 hour at 37 QC,rocking occasionally. The filter was washed with PBS.
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Primary antibodies reactive against the target protein(s ) (diluted 1:100-1: 1000 in 5
% non-fat dried milk in PBS) were added to the filter and incubated at room
temperature for 1.5 hours with constant rocking. The filter was washed again by two
10 min incubations in PBS with constant rocking. Then biotinylated secondary
antibodies (e.g. biotinylated anti-mouse IgG from goat) (diluted 1:500 in 1 % non-
fat dried milk in PBS) against primary antibodies were added on the filter and
incubated at room temperature for 1 hour with constant rocking. The filter was
washed as before and incubated once more at room temperature for 45 min after the
addition of HRP-strepdavidin complex diluted 1:500 in 1 % non-fat dried milk in
PBS. The filter was washed by three 10 min incubations in 1 % Tween-20 in PBS
and one 5 min incubation in PBS. For the detection of target protein bands TMB
stabilised substrate for HRP (Promega) was added on the filter and waited for 10-20
min until the development of a purple colour. The filter was washed for the last time
in H20 and the result was recorded by digitally scanning the filter (Hewlett Packard)
using Deskscan software.
2.8.5 Detection of proteins by ELISA
Detection of antibodies against a target protein in a serum sample was carried by
using an ELISA (enzyme linked immunosorbent assay) method. Target antigen was
diluted to a concentration of 1 ug/ml in 100 mM sodium bicarbonate and 50 III was
applied to each well on a 96 well ELISA plate and dried at 37 QCovernight. Wells
were blocked by the addition of 200 III 5 % w/v non-fat dried milk in wash buffer
(0.244 % (w/v) Tris base, 0.8 % (w/v) NaCl, 0.1 % (v/v) Tween-20, adjusted to pH
7.4 with HCI) for 45 min and then washed 3 times for 5 min each wash with wash
buffer. The serum samples were titrated from 1:30 to 1:7801250 in a 5-fold series in
wash buffer and 50 III were added to the wells (all the wells in row A receiving the
lowest dilution and so on, Figure 4.1). Serum samples were incubated for 2 hours
with the bound antigen in the wells and then the wells were washed with wash buffer
as before to remove unbound antibodies in the serum. Then, 100 III of biotinylated
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anti-rabbit IgG antibodies diluted 1:5000 in wash buffer were added on to each well
and incubated 1.5 hours at room temperature. Wells were washed as before, 100 III
of HRP strepdavidin complex diluted 1:5000 in wash buffer was added on to each
well and incubated 1 hour at room temperature. Once again the wells were washed
as before and 100 III of OPD substrate (10 mg OPD, 9 ml 0.11 M disodium
hydrogen phosphate, 1 ml 0.5 M citric acid and 10 III hydrogen peroxide) per well
was added. After yellow colour development, reactions were stopped by the addition
of 50 IIIof 2.5 M H2S04 to each well and the absorbance of each well at 492 nm was
determined spectrophotometrically by using a 96-well plate reader.
CAT ELISA kit (Boehringer Mannheim) which is based on the sandwich ELISA
principle was routinely used according to the manifacturers instructions in
experiments for the detection of CAT expression in transfected mammalian cell
lysates.
2.8.6 Screening of celllysates for p-galactosidase activity
10 III of cell lysate was placed in a 1.5 ml microcentrifuge tube and Z buffer (16.1
g/ml Na2HP04.7H20; 5.5 g/ml NaH2P04.H20; 0.75 g/ml KCI; 0.246 g/ml
MgS04.7H20, pH 7.0) was added to a final volume of 400 III followed by 5 min
incubation at room temperature. Then, 100 III of freshly prepared 4 mglml ONPG
(o-nitrophenyl p-D-galactopyranoside) in Z buffer was added, mixed by vortexing,
and incubated at room temperature until the samples became yellow. Finally the
reaction was stopped by adding 500 III of 1 M sodium carbonate, mixed by
vortexing, and the absorbance of the samples were measured by spectrophotometry
at420 nm.
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2.9 Purification of GST -fusion Proteins in E.coli
2.9.1 Preparation of small scale crude cell extracts of GST -fusion proteins
Proteins were expressed as glutathione S-transferase fusion proteins in E. coli strain
XLI-Blue. Freshly transformed bacteria were grown in 20 ml LB/ ampicillin (SO
ug/ml) at 37 QCuntil an OD600of O.Swas reached. Fusion protein expression was
induced in the culture by addition of isopropyl-~-D-thiogalactopyranoside (IPTO) to
1 mM final concentration. The culture was then moved to 30 QCand 2 ml sample
was collected at a desired time point post-induction and cells were pelleted by
centrifugation for O.Smin at IS000 rpm in a microfuge. Cells were resuspended in 1
ml ice-cold PBS and lysed by sonication on ice for O.Smin (using Jencons OE37S
ultrasonic processor with microtip set at 4 (power output), SO% duty cycle using 10
sec pulses). The solution was then centrifuged for S min at IS000 rpm in a
microfuge to separate the soluble extract from the insoluble pellet. The sample was
then analysed by SDS-PAOE.
2.9.2 Large scale preparation of GST -fusion proteins
1 L cultures of freshly transformed bacteria were grown to an OD600of O.S and
protein expression induced by addition of IPTO to a final concentration of 1 mM.
The culture was moved to 30 QCand fusion proteins harvested at the desired time
post-induction. Cells were pelleted by centrifugation at 4 QCfor IS min at 1600 g,
washed with 40 ml PBS containing protease inhibitors (SOOJ.1MDTT, SOOJ.1M
PMSF, 10 J.1M leupeptin, 2 J.1M pepstatin A, 10 mM EDTA) then resuspended in 10
ml PBS containing protease inhibitors and frozen at -70 QC.Cells were lysed using a
French pressure press at 1010 psi and cellular debris removed by centrifugation at
32000 g for 60 min at 4 QC.The lysate was diluted to 100 ml in PBS/ 1% Triton X-
100 and incubated with 2 ml of a SO% suspension of glutathione-Sepharose 4B
beads (Pharmacia) for 1 hr at room temperature. The beads were washed four times
in SOml PBS, collected in a column and protein eluted with SOmM Tris-HCI pH 8,
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10 mM reduced glutathione. 0.5 ml fractions were collected and protein
concentrations determined using the BioRad protein assay (section 2.7.1). Finally,
their protein content was assessed by SOS-PAGE and Western blotting.
2.10 Analysis of viral and cellular protein expression
2.10.1 3sS-methionine labelling of cellular proteins
Virus-infected or mock-infected cell monolayers on 60 mm dishes were incubated
with 1 ml of methionine free OMEM (ICN-Flow) for 30 min. Then, 1 ml of
methionine free OMEM supplemented with 100 ~Ci of 35S-methionine [1000
Ci/mmol, Amersham] was added. The dish was incubated for a further 2 hours and
the labelling medium was removed. The cells were washed with ice-cold PBS and
lysed by the addition of 1ml RIPA buffer (150 mMNaCI, 10mM Tris-HCI pH 7.6,
1 % (v/v) Triton X-WO, 1 % (w/v) sodium deoxycholate, 0.1 % (w/v) SOS). The
dish was incubated for 5 min on ice, the lysate was transferred into a microfuge tube,
vortexed and then centrifuged at top speed in a micro-centrifuge. The supernatant
was transferred into a fresh tube and stored at -70°C.
For the labelling of proteins expressed in smaller quantities, cell monolayers were
labelled for 24 hours. This was done by using a slightly modified labelling medium
which consisted of 4 ml of 2 % dialysed FCS, 5 % normal OMEM and 100 ~Ci 35S_
methionine in methionine-free OMEM.
2.10.2 Immunoprecipitation of 3sS-methionine labelled proteins
Antibodies (1-2 J.lIof polyclonal antisera) against the target protein(s) were added to
the radiolabelled, infected or mock-infected cell lysates and incubated for 1 hour at
room temperature on a rotator. Then, 50 ul of protein A sepharose (Sigma) slurry
(slurry was prepared according to the manufacturer's instructions) was added to each
lysate and incubated for a further 30 min at room temperature. The lysate was
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centrifuged in a microcentrifuge at 400 rpm for 2 min and the supernatant was
discarded. The pellet was washed 2-3 times in RIPA buffer and resuspended in gel
loading buffer (see section 2.7.2). The samples were either stored at -70 QCor
immediately boiled for 3 min and subjected to SDS polyacrylamide gel
electrophoresis.
2.10.3 Autoradiography
Autoradiography was done by exposing an X-ray film (Fuji RX) to dried radioactive
gels at -70 QC in complete darkness for at least 12 hours. The film was then
developed and fixed by using chemicals (Kodak) according to the supplier's
instructions.
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Chapter 3
Cloning and sequencing of the
adenovirus 5 Ll-52/55 kD gene
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3.t Introduction
This chapter describes the starting point of the experimental work presented in this
thesis: cloning of the adenovirus type 5 (Ad5) LI-52/55 kD gene.
As stated in the general introduction, the aim of this study was to construct human
cell lines that could complement deletions of Ad5 late genes without a need for a
helper virus. To do this, the missing function(s) had to be supplied by cell lines that
expressed the genes deleted from the virus genome.
To facilitate the expression of the desired genes in cell lines, they had to be first
cloned into suitable vectors (see chapter 5) which would carry out the expression of
the gene(s) within the cells upon transfection.
Although adenovirus DNA can be manipulated directly with restriction enzymes, we
decided to amplify the desired Ad5 gene by peR and directly clone it into a bacterial
plasmid vector designed for the easy cloning of peR fragments. This made the
sequencing and the further cloning of the gene into other plasmids possible due to
the presence of universal primer binding sites and a multiple cloning site.
3.2 peR amplification and cloning of the AdS Lt S2/SS-kD gene
In order to facilitate its cloning, the Ad5 Ll 52/55-kD coding region was amplified
by peR. Primers API and AP2 (Appendix A), containing BamHl and EcoRI
recognition sequences respectively at their 5' ends, were designed according to
published sequence data of Ad5 (Chroboczek et al., 1992) to amplify the Ll 52/55-
kD open reading frame (orf). These primers were homologous to the Ad5 genome at
positions 11050 to 11067 and 12300 to 12281 (on the opposite strand) respectively
(Figure 3.1).
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To be used as a template for the PCR, AdS dl309 DNA was obtained from particles
purified by caesium chloride centrifugation (section 2.2.9) and 100 ng was used for
each PCR. Test PCRs were performed to determine the optimum reaction conditions
for the amplification of LI 52/55-kD orf by using primers API and AP2. Optimum
PCR conditions for this specific amplification were 94 QCfor I min, 55 QCfor I min,
and 72 QCfor 3 min for 30 cycles. The MgC}zconcentration used in the reaction
buffer for this particular pair of primers was 0.75 mM (Figure 3.2).
The 1.3 kb amplification product, containing the LI 52/55-kD orf, was then gel
purified and ligated directly into TA cloning vector pCR II (Invitrogen) (Figure 3.3).
This vector is designed for direct cloning of PCR fragments into a multiple cloning
site (MCS). This MCS is present in the orf of the ~-galactosidase gene a-peptide
and bacterial colonies, of suitable strains, harbouring this gene can be distinguished
by a blue colour when grown on an agar medium containing X-gal (40 mg/ml (w/v)
in dimethyl formamide) (a substrate for ~-galactosidase). If a PCR fragment is
cloned at this position, the orf is disrupted and the colonies harbouring this plasmid
can be distinguished by their white colour. After transformation of E. coli XL-l Blue
with the ligation mixture, positive (white) colonies harbouring pCR II-LI were
checked for the presence of an insert by the colony PCR method, using the primers
API and AP2. One of these colonies was picked for further analysis, which was
done by restriction digestion on purified plasmid DNA, using BamBI and EcoRI
restriction enzymes (Figure 3.4).
3.3 Construction of nested deletions of the cloned Lt gene for DNA
sequencing
Due to the absence of a proofreading activity, Taq polymerase enzyme used in PCRs
has a low fidelity with an error rate of about 2xIO-4 (Dunning et el., 1988), which is
about 104 times higher than a bacterial DNA polymerase (around 8xlO-8).
Considering the possibility of an error being introduced into the amplified sequence
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11050 11070
5' • •ATGCATCCGGTGCTGCGGCAGATGC .
····...··..S;;:;:;HIJ::55_kD AP t ..
start
AP 2 ~~.~~.. .
.............................. GAGGACGGCGAGTACTAAGCG 3'• •
12280 T 12300
L152/55-kD
stop
Figure 3.1 Part of the Ad5 genome coding for L'l 52/55·kD orf
Primers and their direction of polymerization are shown by arrows.
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MgCI2 concentration (tuM)
M 0.25 0.50 0.75 1.00
500bp~
2000bp~
1600bp~
1000bp~
Figure 3.2 Determination of optimum MgCl2 concentration for the
amplification of Ll 52/55-kD orf (1.3 kb) by peR using primers APt and
AP2.
Different concentrations of MgCl2 were used in individual PCRs as indicated
above the lanes. The expected size of the APlIAP2 amplification product was
about 1200 bp. M-dsDNA size marker as indicated.
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Ll
C2hl
peR
amplification
~../." ....,.
,/
'<, ......./..........
<, •••/
.......... . ....
................. .
,...,<,,....., ... / ...//
I
I Ligation
i•
kan'
BamHl
~........
peR II-Ll
'~
EcoRI
amp'
peRil
T/A cloning
vector
amp'
Figure 3.3 peR amplification and cloning of the Ll 52/55-kD. open reading frame
The 1.3 kb amplification product was cloned into vector peR II using the A overhangs
created by Taq polymerase.
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M peR II-LI peR II
500bp
LI 52/55-kD orf
1600 bp
1000 bp
Figure 3.4 Restriction enzyme analysis of plasmid peR I1-Ll
Plasmids peR II-Ll was digested with enzymes BamBI and BcoRI to release the
expected 1.3 kb insert. Plasmid peR II was similarly digested as a control. M-dsDNA
size markers as indicated.
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of Ll 52/55-kD, we decided to subject the cloned 1.3 kb peR fragment to DNA
sequencing analysis because any error introduced at this stage could prevent the
expression of a normal protein in future experiments.
Initial experiments were based on sequencing using primers that were designed to
hybridise with regions were about 300 bp apart, since the number of bases that can
be sequenced by one primer was typically around 300-350 bases. This approach
proved to be unsuccessful because we regularly failed to obtain sequence results
more than 80-100 bases long and some primers did not work at all. This was
probably due to the high Ge content of the DNA to be sequenced. It was therefore
decided to construct nested deletions of the cloned Ll 52/55-kD gene in peR II-Ll
for use in DNA sequencing. Nested deletions are a set of deletions originating at one
end of a target DNA fragment and extending various lengths along the target DNA.
Each successive longer deletion brings new regions of the target DNA into
sequencing range (about 300 bp for normal sequencing gels) of the primer binding
site (figure 3.5).
The method for constructing nested deletions is based on the enzymatic properties of
exo III, a 3' exonuclease specific for double-stranded DNA. Exonuclease III can
initiate digestion at blunt ends or ends with a 5' overhang, but cannot efficiently
initiate digestion at a 3' overhanging end. The protocol contained the following steps
(figure 3.5): (1) cloning of target DNA into a polylinker in a suitable sequencing
vector. Between the target DNA and the sequencing primer binding site there must
be a recognition site for a restriction enzyme that generates a 5' overhanging end or
a blunt end. Also between that restriction site and primer binding site there must be a
recognition site for a restriction enzyme that generates a four base 3' overhanging
end that will thus be protected from exo III digestion. The plasmid vector peR II
used for the cloning of Ll 52/55-kD gene complies with these requirements. (2)
double digestion of peR II-Ll at a site adjacent to the cloned target DNA with an
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enzyme that left a 5' overhanging or blunt end (Spel) and an enzyme that left a 3'
overhanging end of four bases (KpnI). (3) exo III digestion for varying lengths of
time to create unidirectional digestion of the target sequence. (4) treatment with SI
nuclease (a single-stranded nuclease) to remove the 5' single strand, and repair of
ends with Klenow fragment of E. coli DNA polymerase I; and (5) circularization by
ligation with T4 DNA ligase and transformation of competent E. coli cells.
During exo III digestion 10 samples were taken at 1 min intervals and aliquots from
each sample were analysed by agarose gel electrophoresis to check the extent of
digestion (Figure 3.6). After the construction of plasmids containing nested deletions
of the Ll 52/55-kD gene (see section 2.6.1), and transformation of competent
bacteria, one colony from each transformation was picked, plasmid DNA prepared
and analysed by restriction digestion to determine the typical extent of deletion in
the first 7 samples (Figure 3.7 (b) and 3.7 (c». The restriction map of the undeleted
plasmid is represented in figure 3.7(a). Figure 3.7 (b) shows that the first deletion
sample contains two of the expected NsiI fragments (573 and 3747 bp) and lacks the
third fragment (751 bp fragment). Instead, there is a deletion fragment of about 400
bp in length. After digestion with BeoRI and HindlII this same DNA gives two
rather than the expected three bands, one corresponding to a small fragment of 535
bp in length (between the HindIII site in the Ll 52/55-kD gene and the BeoRl site
outside it), another corresponding to a large fragment of 3883 bp in length (between
EcoRI and HindIII sites in the vector); the third fragment, corresponding to the exo
III deleted portion between the two HindIlI sites is absent. From these results, it was
concluded that the exo ill deletion had also extended towards the Kpn1 protected
direction (although to a much smaller extent than in the other direction) stopping just
before Nsil site but abolishing the HindIII site (Figure 3.7 (a». For the deletion
samples 2 and 3, the exo III deletion towards the protected Kpn1 site goes beyond
the Nsil site thus producing two bands after Nsil digestion (Figure 3.7 (bj),
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Ll 52/55kD
Kpnl (3')
Primer binding site
(reverse primer)
I Cut with Spel and Kpnl
5' overhang t
-.....'TT"'r~L;;.I,...:;5..;:2:,..:;/5..;:5.;.:;kD;:;.....,rTT"'1..,-r,.--V__e:..:c,; :.to;.;.r.....;(~p...;;.C.;..R__I .:.I): .. ___ 3' overhang
III1 III!!II J I!I IJ I J J I J J J J J • (protected)
!Exonuclease III digestion(samples taken at varioustime intervals: 1,2,3, ..... ,n)
5' overhang 3'overhang
LlII:IIII DIIII IIIOIII IIIIJIII DII:::rIIIDII:IIIIIOIII============1IIC- (protected)
1_
2_3 _
lSI nuclease digestion
t (creates blunt ends)
I 111111111111111111111 •
2 11111111111111111111 •
3 II 1 I 111111 11111111 •
n
!Klenow DNA polymerase treatmentandligation with T4 DNA ligase
Figure 3.5 Construction of nested deletions of pCR2-Ll for sequencing
The pCR II-Ll plasmid was digested with Spel and Kpnl which generated a 3' overhang next
to the sequencing primer site and a 5' overhang next to the Ll 52/55-kD gene. Digestion
with exo III generated unidirectional deletions from the end with the 5' overhang. Treat-
ment with SI nuclease and repair with Klenow fragment created blunt ends from both the
exo III treated ends and the 3' overhang, which had been protected from the digestion. The
deleted plasmids were circularised with DNA ligase and used to transform E. coli.
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However, although we cannot say towards which direction, it is evident that the
deletion increases progressively at each sample (Figure 3.7 (cj), The results for
deletion sample 4 confirmed that the exo III deletion had extended beyond the Nsi 1
and HindllI sites towards each direction, abolishing these sites. Thus both the Nsil
only and EcoRl, Hindlll digestions produced a single band (Figure 3.7 (b) and (c».
The remaining deletion samples 5-7 also produced only one fragment after Nsil
digestion (Figure 3.7 (b) suggesting the deletions had extended further beyond these
sites. However, only clones from the deletion samples 1-4 were used for the
determination of the sequence of the Ll 52/55-kD DNA since the remaining part of
the Ll 52/55-kD DNA in sample 3 would be short enough to be sequenced in its
entirety.
3.4 Analysis of the sequencing data
The Ll 52/55-kD gene was sequenced completely by sequencing the deletion clones
1-4 using universal reverse primer. The sequence data of the deletion clones
confirmed the outcome of the restriction analysis observed in Figure 3.7.
Comparison of the whole Ll 52/55-kD DNA sequence determined here with the
published Ad5 sequence (Chroboczek et al., 1992) revealed a point mutation
(transition from T to e) at base position 11284, where there should be a Kpnl site
according to the published sequence.
In order to check whether a mutation had been caused by Taq DNA polymerase
during peR amplification or if the virus stock carried a mutation at this position, the
Ad5 genome was subjected to restriction analysis by Kpnl (Figure 3.8). Digestion
of the Ad5 wt300 stock DNA revealed the absence of a Kpnl site, which should be
present in the Ll 52/55-kD coding region according to the published sequence.
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Minutes
M 1 2 3 4 5 6 7 8 9 10
6 kb
5 kb
4kb
Figure 3.6 Ethidium bromide stained gel depicting exo III digestion of peR II·LI.
peR Il-Ll was cut with Spe1 and Kpn1. The linearised plasmid was then subjected to
exo III digestion for 10 different time intervals, followed by SI nuclease digestion.
Approximately 1 ug of each DNA sample was loaded on the gel. The DNA fragments
in the lane labelled "M" are dsDNA size markers, as indicated.
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Nsil
Reverse primer l'
ICAGGAAACAG CTA TG?cCAT GA TTACGCCA AGCTA TTT AG GTGACACf AT AGAATACTCA AGCTATGC~ T
CAAGCfTGGT AC.CGAGCTCG GATCC~CTAG TAACGGCCGC CAGTGTGCTG QAATTCGGCT TTTTTTTGAA: :; ~
-.v -.v -.v Direction of exo III EcoRI
HindIll Kpnl SpeJ
.---___ digestion _-------------------------.------ -----_ ...--, r-------------
I I
I I
iNS¥:Hi~dIll 751bp
Nsil HindllIl' l' 573bp NsilA-
i l' EcoRl (A)
3747bp
.....;> LI52/55-kD
Reverse
primer
M 1 2 4 3 5 6 7
(B)
M 1 2 3 4 M
(C)
Figure 3.7. Determination of the extent of deletion in each deletion sample.
(A) Schematic representation of pCR II-Ll (digested with Kpnl and Spel before
exo III treatment). (B) Single clones from the first seven of the deletion samples,
analysed by Nsil digestion (see text). Lane M:Marker DNA, Lanes 1-7: deletion
samples. (C) Single clones from the first four of the deletion samples analysed
by EcoRl and HindIII digestion (see text). Lanes M: Marker DNA, Lanes 1-4:
deletion samples.
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M Ad5 genome
3000bp
2000bp
1600bp
IOOObp
6485bp
5753bp
5120bp
4811bp
3646bp
2949bp
(A)
2341bp
2048bp
I696bp
I086bp
(B)
2048bp I 6485bp I II 086b~ 1696bp I 5120bp I 3646bp I 2949bp I 4811bp I 2341bp
2749bp
1
3004bP
Kpn1 sites according to the published sequence
2048bp I 6485bp I 5753bp 11086b~ 1696bPI 5120bp I 3646bp I 2949bp I 4811bp I 2341bp
~
Not present
Kpn 1 sites on the genome of the virus stock
Figure 3.8 Restriction analysis of AdS wild type 300 genome by Kpnl.
(A) Ethidium bromide staining of Kpn1 digested Ad5 genome DNA analysed
by agarose gel electrophoresis. M: molecular markers, Ad5: Ad5 genome
digested with Kpnl.
(B) Schematic representation of Kpn1 sites on Ad5 genome and sizes of the
predicted digested fragments (not scaled). "Not present" shows the site that
should be present according to the published Ad5 sequence (Chroboczek et
al., 1992) but which is not present in the wt 300 DNA according to this
analysis.
74
Thus the clone Ll 52/55-kD DNA corresponds exactly in sequence to the template
DNA from which it was derived and the possibility of mutation introduced by the
Taq polymerase was therefore ruled out. Since the templete DNA was derived from
a stock of biologically wild-type virus, it was concluded that this sequence
difference did not affect the function of the Ll 52/55-kD gene.
3.5 Summary
This chapter describes the cloning and sequencing of the Ad5 Ll 52/55-kD coding
region. The sequencing was necessary to confirm the integrity of the cloned gene. A
PCR based cloning strategy was used due to the lack of suitable restriction enzyme
sites flanking the Ll 52/55-kD coding region in AdS genomic DNA. EcoRl and
BamHl sites were incorporated at the 5' ends of the primers used in the PCR
amplification to make subsequent cloning of the gene easier and feasible.
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Chapter 4
Production of antibodies against
adenovirus 5 Ll·52/55·kD protein
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4.1 Introduction
In this chapter I will explain the production of polyclonal antibodies against LI
52/55-kD protein. The aim of producing antibodies against the LI 52/55-kD in this
project was to facilitate the detection of the protein by immunological methods (e.g.
Western blot, immunoprecipitation, ELISA, etc.). For this purpose, I decided to
express the LI 52/55 kD in E. coli as a GST fusion protein to be used as immunogen
for the production of antibodies in rabbit.
E. coli has two characteristics that make it ideally suited as an expression system for
many kinds of proteins to be used as antigens in antibody production: it is easy to
manipulate and it grows quickly in inexpensive media.
In general, GST fusion proteins are soluble and are easily purified from lysed cells
under nondenaturing conditions by adsorption with glutathione-agarose beads,
followed by elution in the presence of free gluthathione (Smith and Johnson, 1988).
If the DNA sequence of the gene coding for the protein of interest is known, this
method is ideal for the expression of proteins to be used as immunogens and allows
researchers to avoid expensive and time-consuming purification of the protein from
celllysates.
The basic approach used to express foreign genes as GST fusions in E. coli begins
with insertion of the gene into an expression vector (e.g. pGEX-2T). This vector
contains several elements: (I) sequences encoding ampicillin resistance «(3-
lactamase) that assure maintenance of the vector in the cell; (2) a controllable
transcriptional promoter (P'ac) which, upon induction by IPTG, can produce large
amounts of mRNA from the cloned fusion gene; (3) a polylinker to simplify the
insertion of the gene in the correct orientation within the vector. Once constructed,
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the expression vector containing the gene to be expressed is introduced into an
appropriate E. coli strain by transformation.
Foreign polypeptides are expressed as fusions to the C terminus of glutathione-S-
transferase (OST), a common 26 kD cytoplasmic protein of eukaryotes. The OST
gene used to generate the pOEX vectors was originally cloned from the parasitic
helminth, Schistosomajaponicum (Smith et al., 1986). The fusion proteins typically
remain soluble within the bacteria and can be purified from lysed cells because of
the affinity of the OST moiety for glutathione immobilized on agarose beads.
Recovery of the fusion proteins is by elution with free reduced glutathione at neutral
pH.
The main advantage of this system for expressing and recovering foreign proteins
from E. coli is that most fusion proteins remain soluble; native proteins over
expressed in E. coli often denature and precipitate. Furthermore, denaturing
conditions are not required at any stage during purification, and consequently,
foreign polypeptides may retain their functional activities and antigenicity.
Additional features are the efficiency and rapidity of purification, the high level of
inducible expression achieved with the strong tac promoter, and the broad range of
suitable bacterial hosts (because the pOEX vectors carry the lacI repressor allele).
The main determinant for successful purification of foreign polypeptides using the
pOEX system is solubility of the fusion protein. To some extent, this can only be
discovered empirically. More difficulties are encountered as the size of the desired
fusion protein increases (particularly when >50 kD), or when the protein contains
regions that are strongly hydrophobic or highly charged. Insoluble fusion proteins
can sometimes be coaxed into solution or can otherwise be purified after
solubilization in denaturing reagents (Smith, 1993).
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After purification, the GST moiety can if necessary be removed from fusion proteins
by cleavage with site-specific proteases at a recognition site encoded within the
polylinker region of the vector. However, often the GST carrier does not com-
promise the antigenicity or functional activity of the foreign polypeptide. Modified
versions of the original pGEX vectors have been produced that simplify cloning,
cleavage or detection of fusion proteins (for review, see Smith, 1993).
4.2 Expression of the Lt protein as a GST -fusion protein
4.2.1 Cloning of Ll gene into a GST -fuslon vector
In order to achieve the expression of LI 52/55-kD gene in E. coli, the Ll 52/55-kD
coding sequence was cloned into the GST fusion protein expression vector pGEX-
2T (Figure 4.2). This vector expresses the cloned Ll 52/55-kD as a GST fusion
protein in frame with GST (see Figure 4.1 and Primer API in Appendix A). The
peR amplified Ll 52/55-kD gene contains a BamHl site at its 5' end. Vector
pGEX-2T also has a BamHl site in its polylinker. The peR-incorporated BamHI
site was designed so that cloning of Ll 52/55-kD gene by the use of the BamHl site
placed it in frame with the GST coding sequence (Note that there are other pGEX
vectors in which the cloning sites are present in different reading frames, so the right
vector can be chosen (Pharmacia).).
The cloning was done by digestion of the plasrnids peR IT-Ll and pGEX-2T with
BamHl and EcoRI enzymes (figure 4.2). The relevant fragments from both
reactions were purified from agarose gels after subjecting the reaction mixtures to
agarose gel electrophoresis. The Ll 52/55-kD fragment and the pGEX-2T vector
backbone were ligated and the ligation mixture was used to transform E. coli. XLI-
Blue strain. The resultant ampicillin (amp) resistant colonies were replica plated to
kanamycin (kan) agar plates and growth compared with the original ampicillin
plates. Colonies which were kan-sensitive (the ones which did not contain peR II
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backbone) were subjected to colony peR analysis, using primers API and AP2, in
order to check the presence of Ll 52/55-kD DNA. One colony which showed a band
corresponding to the right size of 1250 bp after the peR analysis (Figure 4.3 (a»
was picked for further analysis. Plasmid DNA from this colony was prepared in
small scale and analysed by digestion with BamHi and EcoRI restriction enzymes
(Figure 4.3 (bj), This analysis confirmed the presence of LI 52/55-kD DNA within
the pGEX-2T vector.
4.2.2 Analysis of the expression and purification of the GST -Ll fusion protein
Although GST fusion proteins are usually stable in E. coli, if the protein coded by
the insert DNA is bigger than 50 kD the fusion product can be degraded extensively
due to the instability of the large protein. After the confirming that the LI 52/55-kD
cDNA had been cloned into the GST fusion vector pOEX-2T, the next step was to
ask whether the GST -LI 52/55-kO protein was being expressed in detectable levels
in E. coli. To do this, an overnight culture of the strain harbouring plasmid pOEX-
2T-Ll was diluted 1/100 in fresh medium and incubated until a culture density of
00600 0.5 was reached. At this level the culture was divided into two and in one of
the cultures, the expression of GST-LI fusion protein was induced by the addition of
O.lmM IPTO to the medium. Samples were taken from both induced and uninduced
cultures at 0 hr, 2 hr, 4 hr and 6 hr intervals and the cells in each sample were lysed
by sonication. Insoluble material was separated by centrifugation and the
supernatants were used for analysis on SOS-polyacrylamide gel electrophoresis
(Figure 4.4). Analysis of the gel after staining with Coomassie blue showed
increasing amounts of a novel, induced protein as the duration of induction increased
(lanes 3 to 5). In the sample collected at 0 hr there was not any detectable level of
this protein (lane 2). When compared with the marker protein molecular weights
(lane 1), it can be seen that this protein had a molecular weight of around 70 to 75
ko. This was roughly equal to the size of the expected GST-Ll (26 ko + 48 kO)
fusion protein. The same protein was seen in the uninduced sample
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BamHI Smal EcoRI (-924)
EcoRV
(-4070)
pGEX1
4932 bp
Pstl
(-1881 )
thrombin
Pro Lys Ser Asp iLeu Val Pro Arg tGly Ser I Pro Gly lie His Arg Asp STOP
pGEX2T CCA AAA TCG GAT CTG GTI CCG CGT GGA TCC CCG GGA ATI CAT CGT GAC TGA CTG
8amHI Smal EeaRI
Figure 4.1 GST fusion protein expression vector.
PGEX-2T is a fusion protein expression vector that expresses a cloned gene as a
fusion protein to GST. The lac repressor (product of the lacI gene) binds to the P,ac
promoter, repressing the expression of GST fusion protein. Upon induction with
IPTG, derepression occurs and GST fusion protein is expressed. The gene of
interest can be inserted into the polylinker located at the end of the GST gene. The
polylinker sequence is shown below the map of pGEX-2T, where the restriction
endonuclease and protease cleavage sites are bracketed.
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ColE10ri
8amHI
EcoAI
pGEX-2T
4929 bp
pCRII-L1
5203 bp
EeoR! &
BamH! digestion
EeoR! &
BamHl digestion
Ligation
EcoRI
pGEX-2T L1
6177 bp
Figure 4.2 Cloning of Ll 52/55-kD into GST fusion protein
expression vector pGEX-2T.
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M 1 2 3 4 5 6 7 8 9 10 11 12 l3 14
1000 bp
(A)
1600 bp
Ll (B)
_ ...........52/55-kD
~ lOOObp
Figure 4.3 peR and restriction analysis of transform ants for
pGEX-2T -r.i,
(A) peR analysis of kan-sensitive colonies by primers ApI and Ap2.
M: molecular markers, 1-14: transformants analysed.
(B) Restriction analysis of plasmid DNA from transformant 6 by
enzymes EcoRI and HindIII. M: molecular markers, 6: transformant 6,
c: control DNA pGEX-2T.
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collected at 6 hr post-induction (lane 6), however, at a much lower amount. This
could be attributed to leaky expression from the Ptac promoter. Although from this
experiment it was difficult to say the extent of the degradation of the fusion protein,
the presence of detectable levels of the GST-Ll 52/55-kD fusion protein was an
encouraging result. In order to investigate in detail the stability of the fusion protein,
it was purified in large scale from a 500 ml culture volume by affinity
chromatography (see materials and methods) on glutathione agarose and aliquots
from each fraction were analysed by SDS-polyacrylamide gel electrophoresis.
Constant volumes of each fraction were analysed on two separate gels; one of these
was stained with Coomassie blue and the other was used for the detection of the
fusion protein by Western Blotting using anti-GST rabbit antibodies (Figure 4.5).
Comparison of the stained SDS-PAGE gel with Western blotted membrane would
easily differentiate between non-GST and GST-fusion protein (intact or degraded)
and give us an idea about the purity of the GST-Ll fusion protein stock that was
intended to be used for the immunization of a rabbit for the production of antibodies
against Ll protein. As it can be seen from the Figure 4.5 all the bands that were
visible after the staining of the gel (panel A) were also detected by the anti-GST
antibodies (panel B), producing bands of equivalent relative intensities in each case.
This indicated that the protein was of high purity. What this figure also showed was
that the fusion protein was not entirely intact but degraded to a certain extent. Since
the bands smaller than the expected fusion protein were also detected by the anti-
GST antibodies, they were concluded to be degradation products of the GST-Ll
52/55-kD fusion protein.
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induced uninduced
M 1'·0....·....·..2 ..........··4··········......6··1 6
30kD
GST-Ll
fusion protein
97.4 kD
66kD
46kD
Figure 4.4 Analysis of the expression of GST -Ll fusion protein
M: molecular size markers, induced: samples taken after the induction of
the Ptacpromoter by IPTG, Uninduced: sample taken before the induction.
numbers indicate the time (in hours) intervals the samples were taken post
induction
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fraction fraction
M 2 3 4 5 M 2 3 4 5
66kD~
97.4kD+-
(A) (B)
Figure 4.S Large-scale purification of GST-Ll S2/SS-kD fusion protein
by affinity chromotography.
Aliquots from each fraction collected during elution from glutathione-
agarose were analysed by SDS-PAGE and proteins detected by Coomassie
blue staining/A) and by Western Blotting using anti-GST antibodies CB).
M: Molecular size markers, 1-5: eluted fractions from affinity chromotography
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4.3 Antibody production
The typical kinetics of the development of a specific antibody response upon
immunization with antigen is illustrated in Figure 4.6. After the primary
immunization, naive B cells are stimulated to differentiate into antibody-secreting
plasma cells. For most soluble protein antigens, specific antibody begins to appear in
the serum 5 to 7 days after the animal is injected. The antibody concentration (titer)
continues to rise and peaks around day 12, after which it decreases (Klinman and
Press, 1975).
In addition to differentiating into antibody-forming cells, the antigen-stimulated B
cells proliferate to form a large population of "memory" B cells, which quickly
become activated after further antigen is administered. Thus, the lag period before
the appearance of the specific antibody is much shorter after a booster injection than
that observed for the initial immunization. In addition, a significantly higher titer of
specific antibody is achieved and is sustained for a longer period of time. The peak
of antibody production occurs 10 to 14 days after boosting. As a consequence of the
existence of the memory B cells, less antigen is required to stimulate a strong
secondary response. Memory B cells are long-lived, therefore a specific antibody
response can be elicited 6 months to a year after the last booster. Finally, the average
affinity and degree of specificity of the antibody population for the antigen increase
with repeated immunizations (Klinman and Press, 1975).
Adjuvants administered with an antigen dose greatly enhance the specific antibody
titer, as they allow the antigen to be released slowly, ensuring the continual presence
of antigen to stimulate the immune system. Freund's adjuvant is most commonly
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Figure 4.6 Typical kinetics of development of a specific antibody
response.
Arrows indicate the timing of priming and boosting immunization.
Actual amounts of specific antibody produced will vary considerably
depending on immunogenicity of the protein.
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used in the preparation of antisera because it induces a high, long-lasting antibody
titer that is often still measurable 25 weeks or more after boosting. The presence of
mycobacteria in complete Freund's adjuvant non-specifically activates the T-cell
population, ensuring that lymphokine production is maximal for B-cell stimulation.
Complete Freund's adjuvant may cause granulomas, however, and can therefore be
used only for primary immunization. Incomplete Freund's adjuvant, lacking the
mycobacteria is adequate for booster injections.
4.3.1 Immunization of rabbit against GST -Ll fusion protein
Polyclonal antiserum was raised against GST -Ll 52/55-kD fusion protein by
subcutaneous injection into an outbred half-lop rabbit. Approximately 300 Ilg of
purified fusion protein, in Freund's complete adjuvant, was used for the initial
immunization, which was followed by four successive booster immunizations with
300 ug of protein in Freund's incomplete adjuvant in each case. Serum was obtained
before each immunization and tested for GST -Ll 52/55-kD by indirect ELISA
(Figure 4.7). Specific antibodies were detected by coating the wells of a microtiter
plate with antigen (GST -Ll 52/55-kD fusion protein), incubating the coated plates
with dilutions of serum samples obtained before each immunization, and washing
away unbound antibodies. A solution containing biotinylated anti-rabbit IgG
antibodies was then added onto each well. After incubation, unbound anti-rabbit
antibodies were washed away and detection was performed by the addition of the
substrate for HRP which produces a colour upon hydrolysis of the substrate. The
hydrolyzed substrate amount, which was assessed with a spectrophotometer, is
proportional to the amount of specific antibody in the test solutions. The results
presented in Table 4.1 clearly showed a reactivity between the collected antisera and
the GST-Ll 52/55-kD fusion protein. The reactivity increased further in each
collected sample until week 12 of the immunisation schedule. For the sample
collected at week 16, the reactivity was comparable to the levels seen for the week
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with antigen
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antibody-enzyme conjugate
add substrate and observe
colour change or fluorescence
Figure 4.7 Indirect ELISA to detect specific antibodies.
Ageantigen; Ab=antibody: Eeenzyme
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Dilution Pre bleed post4 postS post 12 post 16
factor weeks weeks weeks weeks
1:10 1:893 over over over over
1:50 1.107 2.137 2.384 over over
1:250 0.650 1.889 2.184 over 2.352
1:1250 0.375 1.677 2.172 2.277 2.245
1:6250 0.231 1.039 1.955 2.150 2.069
1:31250 0.136 0.437 1.452 1.133 1.775
1:156250 0.102 0.072 0.522 0.734 0.841
1:7S01250 blank 0.032 0.158 0.203 0.236
Table 4.1 Indirect ELISA test on sera collected after immunisation with GST·
Ll 52/55·kD protein.
Specific antibodies bound to GST-Ll 52/55-kD fusion protein were detected with
biotinylated anti-rabbit antibodies and streptavidin-HRP complex. After addition of
a colourimetric substrate for HRP, absorbance was read at 490nm.
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12 sample, suggesting that the maximum specific antibody levels had been reached.
4.3.2 Immunoprecipitation of Ll protein from AdS infected 293 cells
Although the antisera collected from the immunized rabbit were shown to react with
the GST-Ll 52/55-kD fusion protein by ELISA, this result could be due to the
presence of anti-GST antibodies reacting with the GST part of the fusion protein. In
order to confirm the presence of antibodies reactive against the Ll 52/55-kD protein,
adenovirus infected and mock-infected 293 cells were radiolabelled with 35S_
methionine and all the cell extracts were immunoprecipitated with either pre-
immune or 8 weeks post-immunization serum (figure 4.8). As a positive control for
the determination of Ad5 infection, 3sS-methionine labelled Ad5 or mock infected
293 cells were immunoprecipitated by monoclonal antibodies against Ad5 DBP
(Reich et al., 1983). The result of this immunoprecipitation experiment indicated the
presence of a band corresponding to Ll 52/55-kD protein, only in the Ad5-infected
cell extracts when immunoprecipitated with the immune serum. Two separate bands
corresponding to differentially phosphorylated forms of the Ll protein as previously
reported (Lucher et al., 1986) (52 kD and 55 kD respectively) were not
distinguishable in this autoradiograph. This was most probably due to the high
amount of each protein making the two bands appear as a large single band.
Alternatively, the labelling protocol used may have differentially labelled the newly
synthesised, under-phosphorylated form.
4.4 Summary and Discussion
In this chapter I have described the production of polyclonal antiserum against the
Ad5 Ll 52/55-kD protein. I chose to express the Ll 52/55-kD protein as a GST
fusion protein in E. coli by using a suitable GST fusion protein expression vector
(pGEX-2T). After its purification, the GST-Ll 52/55-kD fusion protein was used for
the immunisation of a rabbit and serum collected prior to each booster
immunizations, with four weeks time intervals. This approach yielded a high titre
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Figure 4.8 Immunoprecipitation of Ll 52/5S-kD protein from AdS-
infected cells.
Ad5 or mock-infected 293 cells were radiolabelled with 35S-methionine
and total cell extracts immunoprecipitated by using either anti-GST-L1
52/55-kD pre-immunisation serum or anti-GST-L1 52/55-kD 8 weeks
post-immunisation serum or anti-DBP monoclonal antibodies. Immunopre-
cipitation by anti-DBP monoclonal antibodies was done as a positive
control to determine Ad5 infection in the experiment.
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antiserum with reactivity against the Ll portion of the fusion protein An alternative
method for raising specific antibodies would have been the use of a synthetic peptide
corresponding to a region of the predicted amino acid sequence of the Ll 52/55-kD
protein for the immunisation of the rabbit. The advantages of such a strategy would
be its shorter time requirement and the production of antibodies specific to a much
smaller number of the epitopes present on the Ll 52/55-kD protein. Such an
antiserum would be expected to contain anti-Ll 52/55-kD antibodies showing no or
little specific interaction with other viral or non-viral proteins. On the other hand,
due to the small and relatively much less complicated structure of such a synthetic
peptide, it might had not been as efficient as the whole protein in stimulating an
immune response in the rabbit, thus the antibody titers specific to the peptide could
have been very low. Since the Ad5 Ll 52/55-kD protein is modified post-
translationally in the host cell by differential phosphorylation, the antibodies raised
against a synthetic peptide might not recognize the modified protein produced by the
infected host cell.
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Chapter 5
Construction of cell lines expressing
adenovirus 5 late genes
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5.1 Introduction
Construction of adenoviruses deficient in viral genes responsible for the replication
and growth of virus requires the use of either an helper virus or complementing cell
lines expressing the missing viral genes. The use of a helper virus is generally not
desired due to the high risks of contamination of the recombinant virus stocks with
the helper virus. In this chapter, I will describe the construction of complementing
cell lines with the aim of producing replication-deficient Ad5 recombinants deficient
in one or more late genes.
In previously published work, an Ad5 pIX-deficient mutant was constructed and
complemented by a 293 cell line expressing the Ad5 pIX protein (Caravokyri and
Leppard, 1995). Since the aim was to produce highly deleted AdS recombinant virus
deficient in Ll S2/S5-kD and/or other late genes, it was decided to make
complementing cells lines expressing AdS Ll S2/SS-kD, Ll S2/SS-kD plus pIX and
Ll S2/S5-kD plus IVa2 genes in order to be used to construct only Ll S2/SS-kD,both
Ll S2/SS-kD and pIX and both Ll S2/SS-kD and IVa2 deleted viruses respectively.
The planned strategy was first to construct the Ll S2/SS-kD deleted virus. Upon
construction of such a virus the next step would be to construct viruses containing
the deletions of Ll S2/SS-kDwith pIX and Ll 52/55-kD with IVa2 genes.
There are two widely used methods for the constitutive expression of proteins in
eukaryotic cell lines. The first one of these methods involves the integration of DNA
containing an expression cassette of the desired protein into the host cell genome.
By this way, the integrated copy of the gene expressing the desired protein is
maintained in a stable form and passed onto to next generation of cells without being
lost. However, the amount of protein produced from the integrated expression
cassette is variable and was anticipated to be too low for effective complementation
of adenoviruses deficient in functions normally expressed to high levels late in
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infection, due to the presence of a single copy of the expressed gene in each cell.
The second method involves the episomal expression of the desired gene in the
nucleus of the transfected cells. In this method, the gene to be expressed is cloned
into a Epstein Barr Virus (EBV)-based plasmid vector which is maintained as
multiple copies/cell by episomal replication in the host cell nucleus, hence
expressing high levels of recombinant proteins.
EBV based vectors are maintained extrachromosomally in primate and canine cell
lines (Chittenden, et al., 1989) and offer the following features (Figure 5.1): ColEl
origin of replication and ampicillin-resistance gene for growth selection in E.coli;
the EBV origin of replication (onP) and nuclear antigen gene (EBNA-l) to allow
high copy episomal maintenance; a selectable marker gene (e.g. hygromycin-
resistance) for stable maintenance of the vector; a multiple cloning site flanked by a
strong promoter and a polyadenylation signal for the cloning and expression of the
recombinant protein. OriP and EBNA-l are necessary for the extrachromosomal
maintenance of the plasmid in mammalian cells. EBNA-l protein acts as both an
enhancer and an activator of the EBV oriP. Cells transfected with such a plasmid
(e.g. pMEP 4) can be selected by growing them in a medium containing the
appropriate drug (e.g. hygromycin). Generally, as the concentration of the drug used
for the selection of the plasmid increases, the copy number of the plasmid increases
and higher levels of recombinant protein expression are achieved. The highest
possible drug concentrations that do not affect the cell growth have to be determined
experimentally for different types of cell lines.
5.2 Constitutive episomal expression of the AdSLt gene in 293cells
To express Ll 52/55-kD from a strong promoter, the Ll 52/55-kD open reading
frame from plasmid pCR IT-Ll was cloned downstream of the human
cytomegalovirus immediate early (CMV-IE) promoter in an episomal expression
vector, pMEP-CMV (figure 5.5). This is a very strong constitutive promoter and
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!:Bgill
Asp718
Kpnl
Pvull
Hindlll
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BamHI
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10440 bp
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Figure 5.1 pMEP4: An EBV -based episomal mammalian expression vector
(Invitrogen)
pMEP9 is maintained extrachromosomally in primate and canine cell lines (Chittenden
et al., 1989) and offers the following features: ColEl origin of replication and ampicillin
resistance gene for growth selection in E.coli; the EBV origin of replication (oriP) and
nuclear antigen (EBNA-l) to allow high copy episomal expression; a selectable marker
(hygromycin-resistance gene) flanked by a promoter and a polyadenylation signal
sequence for stable maintenance of the vector; a MCS flanked by methallothionine
promoter and another polyadenylation signal for the cloning and expression of the
recombinant protein.
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expresses high levels of protein from an open reading frame located downstream
(Boshart et al., 1985).
Plasmid pMEP-CMV is based on pMEP4 (Invitrogen; Figure 5.1) and was
constructed by the replacement of the methallothionine promoter with the CMV-IE
promoter from plasmid pCMV-55K (White and Cipriani, 1990) through a series of
cloning steps (Figures 5.2-5.5). Cloning of the Ll 52/55-kD cDNA into pMEP-
CMV produced the plasmid pMEP-CMV-Ll (Figure 5.6), the structure of which
was confirmed by restriction analysis (not shown).
To construct 293 cell lines expressing the AdS Ll 52/5S-kD protein, multiple 60 mm
dishes of 293 cells (60-80 % confluent) were transfected with the plasmid pMEP-
CMV-Ll (1 ug per 60 mm dish) and the cells were incubated for 24 hours before the
addition of fresh medium containing hygromycin. Different concentrations of
hygromycin (50-300 Jlglml) were added to each plate and incubation continued for
several weeks (replacing the medium in each dish regularly with fresh medium
containing hygromycin) until stable cell lines growing at a rate comparable to wild
type 293 cells (i.e. could be passaged at a 1 in 4 area split every 3-4 days) were
established.
To check the level of expression of the Ll 52/55-kD protein in each cell line grown
in the presence of different concentrations of hygromycin, cell lysates from 60 mm
tissue culture dishes were analysed by Western blotting using polyc1onal antibodies
raised against Ll S2/55-kD. Cells lines grown in the presence of 200 ug/ml
hygromycin showed the highest amount of Ll 52/55-kD protein expression (data not
shown). Propagation of this cell line was continued, and upon confirmation of the
expression by another Western blot (Figure 5.7), the cell line was named 293-Ll cell
line. As it can be seen in the Figure 5.7, the Ll 52/55-kD protein expression in 293-
Ll cells is at comparable levels to the expression in Ad5 infected 293 cells lysed at
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Figure 5.2 Construction of pMEP-CMV (step 1)
The CMV promoter from pCMV-55K was cloned as a Clal-EcoRI fragment
into pBR322.
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Figure 5.3 Construction of pMEP·CMV (step 2)
The CMV promoter from pBR322-CMV was cloned as a HindIII-EcoRI
fragment into pCR II.
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Figure 5.4 Construction of pMEP-CMV (step 3)
The CMV promoter from pCR II-CMV was cloned as a Hindlll-Xhol
fragment into pMEP4.
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Figure 5.5 Construction of pMEP·CMV (step 4)
Deletion of the Pmetpromoter from pMEP4-CMV by Xbal and Nhel digestion
and religation.
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Figure 5.6 Construction of pMEP-CMV -Ll
Insertion of the Ll 52/55-kD eDNA into p:MEP-CMV as a BamHl fragment
into p:MEP-CMV.
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18-20 hours post-infection. As expected, there is no expression at all in 293 cells.
5.3 Complementation of Ad5 Lt mutants by 293·Ll cell lines
To assess the degree of complementation afforded by 293-L1 cells, Ad5 mutants
ts369 (Hasson et al., 1989) and H5pm8001 (Gustin and Imperiale, 1998) were used.
Ad5 ts369 produces L1 52/55-kD proteins with a two amino acid substitution and its
ability to form plaques is temperature-sensitive. The yield of ts369 is reduced by a
factor of 103 when it is propagated at 39.5 °c (non-permissive temperature) as
compared with 32°C (permissive temperature). On the other hand H5pm8001 is an
L1 null mutant incapable of expressing the 52/55-kDa protein at all.
A complementation assay for Ad5 ts369 was devised in order to investigate the level
of complementation, if any, provided by the 293-Ll cells (Figure 5.8). Two 60 mm
dishes of both 293 and 293-L1 cells were infected with ts369 with a multiplicity of
infection (moi) of 10 pfu for each dish. One dish from each cell type was incubated
at permissive temperature (32°C) and the remaining dishes were incubated at non-
permissive temperature (39.5 QC).Also two 60 mm dishes of 293-Ll cells were
infected with wild type Ad5 (moi=lO pfu) as controls, and while one of them was
incubated at permissive temperature, the other one was incubated at non-permissive
temperature. After an incubation period of 3 days, virus was harvested from each
infected dish by three freeze & thaw cycles and dilutions from each were assayed for
plaque formation on 293 cells at the permissive temperature (Figure 5.9).
Ad5 mutant ts369 grown at non-permissive temperature in 293 cells lines produced
a titre of 2x106 pfulml, 1000 fold lower than the titre when grown at the permissive
temperature which was 2x109 pfulml. This result is consistent with the one
published by Hasson et al., 1989. On the other hand, growth of the ts mutant in 293-
L1 cells at the non-permissive temperature produced a titre of 6x108 pfulml while
growth at the permissive temperature produced a titre of 4x 109,Compared to the ts
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Figure 5.7 Analysis of Ll S2/55-kD protein expression in hygromycin
resistant 293 cells transfected with plasmid pMEP-CMV-Ll by
western blotting
Celllysates from mock-infected (293),Ad5-infected (Ad5) 293 cells
and 293-Ll cells were immunoblotted by using anti GST-Ll polyclonal
antibodies. M- protein molecular mass markers.
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mutant virus titre when grown at permissive temperature in 293 cells, there was a
two-fold increase in the titre when the ts mutant virus was grown at the same
temperature in 293-Ll cells. Although not a big difference, this two-fold increase in
the virus titre was most probably due to the higher levels of Ll 52/55-kD protein
present in the 293-Ll cells.
However, when a comparison was made between the virus titre of the ts mutant
grown in 293 cells at the non-permissive temperature and in 293-Ll cells at the
same non-permissive temperature, there was a 300-fold increase in the titre of the
ts369 virus grown in 293-Ll cells. This 300-fold increase in the virus titre showed
the level of complementation of the ts mutant virus by the 293-Ll cell line and thus
proved that this cell line was expressing the Ll 52/55-kD protein in a biologically
functional form. In the control experiment, where wild-type adenovirus was grown
in 293-Ll cells at both permissive and non-permissive temperatures, there was no
marked difference in the virus yield. This observation ruled out the possible effects
of temperature shift on the wild-type virus titres.
In another experiment, the adenovirus Ll null mutant H5pm800 1 was used for a
similar complementation assay. This time, both wild-type and LI null mutant
(H5pm8001) viruses were grown in two type of cell lines, 293 and 293-LI (figure
5.10). Virus was harvested from the cells three days after infection and the virus titre
was determined by plaque assay on 293-LI cells (figure 5.11).
H5pm8001 produced a titre of 1.5xl06 pfu/ml in 293 cells, around IOOO-foldlower
than the titre obtained from wild-type virus grown in the same 293 cell lines (lx109
pfu). This difference was consistent with the result published by Gustin and
Imperiale (1998). Growth of the wild type virus in 293-Ll cell lines led to a minor
increase in the titre (around 4-5 fold) when compared with the titre obtained from
growth in 293 cells. However, the Ll null mutant virus H5pmSOO1 titre was
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Figure 5.8 Experimental setup for the complementation assay using Ad5
mutant ts369
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Figure 5.9 Complementation assay of the adenovirus mutant ts369
by the 293-Ll cell line.
Wild-type virus was grown in 293 L1 cells and L1 temperature mutant
ts369 virus was grown in two cell lines, 293 and 293-Ll (figure 5.8).
The cells were infected with the relevant virus at an moi of 10 pfu.
Virus was harvested from the infected cells three days after the
infection and the virus titre was determined by plaque assay on 293-Ll
cells. Error bars show the standard deviation of results obtained in
three independent complementation experiments calculated according
to the equation shown in Table 7.1.
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drastically increased (around 200-fold) when it was grown in 293-Ll cells. This
increase was comparable to the 300-fold increase obtained in the complementation
assay for the ts369 and once again showed that the 293-Ll cells were capable of
complementing the Ll 52/55-kD protein deficiency during an infection of this cell
line by a mutant adenovirus incapable of expressing the Ll 52/55-kD gene.
These results obtained from both complementation assays were encouraging and
indicated that the 293-LI cell line could successfully complement a missing Ll
52/55-kD protein function during my attempts to construct an Ll 52/55-kD gene-
deleted adenovirus in the future experiments.
5.4 Constitutive episomal expression of the AdS IV~ and pIX genes in 293·
Lt cells
Confirmation of the capability of the 293-Ll cells to complement the Ad5 Ll 52/55-
kD protein deficiency in Ad5 mutants ts369 and H5pm8001 let me proceed to
construct cell lines expressing other Ad5 late genes, IVa2 and pIX respectively in
293-Ll cells. The main aim of construction of such cell lines was to use them as
complementing cell lines for the construction of recombinant Ad5 lacking IVa2 or
pIX coding regions together with Ll 52/S5-kD coding region. These cell lines were
also required for experiments to investigate the effects of Ad5 late proteins in the
activation of Ad5 major late promoter (see chapter 7).
Construction of 293 cell lines expressing AdS Ll 52/55-kD and 1Va2 proteins or Ll
52/55-kD and pIX proteins involved the coexpression of the relevant proteins in the
same cell. Potentially, the cDNAs encoding the relevant proteins could be cloned
and expressed from the same expression vector provided that each cDNA was
flanked by a different promoter and polyadenylation sequences. However, since a
cell line expressing the Ad5 Ll 52/55-kD protein was already constructed, it was
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Figure 5.10 Experimental setup for the complementation assay on AdS
mutant HSpm8001
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Figure 5.11 Complementation assay of the AdS Ll null mutant
HSpm800l by the 293-Ll cell line.
Wild-type and L1 null mutant (H5pm8001) viruses were grown in two
type of cell lines, 293 and 293-L1 (figure 5.10). The cells were infected
with the relevant virus type with a moi of 10 pfu. Virus was harvested
from the infected cells three days after the infection and the virus titre
was determined by plaque assay on 293-L1 cells. Error bars show the
standard deviation of results obtained in three independent
complementation experiments calculated according to the equation
shown in Table 7.1.
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decided to use a separate episomal expression vector for the expression of the
second AdS protein (IVa2or pIX). Such a coexpression strategy required the use of
different selectable markers for each expression vector in order to amplify and select
them independently from each other. This ensures the selection of cells harbouring
both vectors driving the expression of the different cloned cDNA molecules when
grown in the presence of the relevant antibiotics for which the genes present on the
vectors provide resistance.
For this purpose, cDNAs of the AdS IVa2 and AdS pIX genes were cloned into
another EBV-based mammalian episomal expression vector, pREP9 (figure S.12).
This plasmid has similar features to pMEP4 (figure S.1) except that it contains the
RSV promoter instead of the metallothionine and also a 0418 (neomycin) resistance
gene instead of the hygromycinB resistance gene present on pMEP4.
To be used in the construction of 293 cell lines expressing AdS Ll S2/SS-kD and
AdS IVa2genes (293-LI-IVa2), IVa2 cDNA from plasmid pIVa2 was cloned into the
multiple cloning site of pREP9 downstream the RSV promoter (figure S.13 (a».
Similarly, for the construction 293 cell lines expressing AdS Ll S2ISS-kDand AdS
pIX (293-Ll-pIX), pIX cDNA from plasmid pCMV-IX was cloned at the same
position of pREP9 (figure S.13 (b». Constructed plasmids were named as pREP9-
IVa2 and pREP9-IX respectively.
Construction of the 293-LI-IVa2 and 293-Ll-pIX cell lines was done using the same
methodology as described for the construction of the 293-Ll cell line (section S.2)
except that varying concentrations of 0418 were used instead of hygromycinB. To
maintain expression of Ll S2/5S-kD, a fixed concentration of hygromycinB (200
ug/ml) was also included in the growth medium.
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Figure 5.12 pREP 9: An EBV·based episomal mammalian expression vector
(Invitrogen)
pREP 9 is maintained extrachromosomally in primate and canine cel11ines
(Chittenden et al., 1989) and offers the following features: ColEl origin
of replication and ampicillin resistance gene for growth selection in E.coli;
the EBV origin of replication (oriP) and nuclear antigen (EBNA-l) to allow
high copy episomal expression; a selectable marker (neomycin-resistance gene)
flanked by a promoter and a polyadenyla ion signal sequence for stable maintenance
of the vector; a MCS flanked by RSV promoter and another polyadenylation
signal for the cloning and expression of the recombinant protein.
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Figure 5.13 Construction of pREP9-IVa2 (a) and pREP9-IX (b).
For the construction pREP9-IVa2, AdS IVa2 cDNA from plasmid pIVa2 was
cloned in to the MCS of the plasmid pREP9 by using BamHi restriction
enzyme (a) and similarly for the construction of pREP9-IX, AdS pIX cDNA
was cloned into the MCS of pREP9 again by using BamHi restriction
enzyme (b). The orientation of cloned inserts was confirmed by restriction
analysis (data not shown).
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Figure 5.14 Analysis by Western blotting of pIX (a) and IVa2 (b) protein
expression in G418 resistant 293 cells transfected with plasmid pREP 9-
IX and pREP 9- IVa2 respectively.
(a) Celllysates from mock-infected (293) or AdS-infected (AdS) 293 cells.
293-Ll cells and 293-LI-IX cells were immunoblotted by using anti GST-pIX
polyclonal antibodies.
(b) Celllysates from mock-infected (293) or AdS-infected (AdS) 293 cells,
293-Ll cells and 293-Ll-IVa2 cells were immunoblotted by using anti GST- IVa2
polyclonal antibodies.
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To check the level of expression of the Ll 52/55-kD and IVa2 proteins or Ll 52/55-
kD and pIX proteins in each cell line grown in the presence of different
concentrations of 0418, cell lysates were analysed by Western blotting using
polyclonal antibodies raised against Ll 52/55-kD (Chapter 4), IVa2 (Brey, 1999) and
pIX (Caravokyri and Leppard 1995). Cells lines grown in the presence of 300 ug/ml
0418 showed the highest amount of IVa2 and pIX expression in 293-LI-IVa2 cells
and 293-Ll-pIX cells respectively (data not shown). Propagation of these cell lines
was continued, and upon confirmation of the expression by another Western blot
(figure 5.14), several aliquots from each cell line were stored by freezing in liquid
nitrogen to be used in future experiments.
5.5 Summary and Discussion
In this chapter I have described the construction of 293 based cell lines 293-Ll, 293-
LI-IVa2, and 293-LI-IX expressing Ad5 proteins Ll 52/55-kD, Ll 52/55-kD and
IVa2, and Ll 52/55-kD and IX respectively in order to be used as complementing
cell lines. These were designed to supply in trans the relevant proteins that would be
missing during attempts to construct recombinant viruses with deletion mutations in
these gene(s). Although the 293-Ll cells were shown to be expressing the Ll 52/55-
kD protein by Western blotting experiments, the functionality of the expressed
protein could not be demonstrated by this method. Another concern about the
expressed Ll 52/55-kD protein was that the constituve presence of this protein in the
cells prior to infection could affect the normal replication cycle of an Ll 52/55-kD
deleted virus. This could have unpredictable effects and even cause decrease in the
virus titers rather than increase by complementation. Thus, in order to test both the
functionality and the complementing ability of the 293-Ll cells, a complementation
assay was devised to compare the titers of Ll 52/55-kD mutant viruses grown in 293
and 293-Ll cells. The Ad5 Ll 52155-kD mutants used for this purpose were ts369
and H5pm8001. These viruses contained a ts or null mutation in the Ll 52/55-kD orf
respectively and were both shown to be complemented by the 293-Ll cells.
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Chapter 6
Attempts to construct Ll-52/55-kD
deleted adenovirus 5 recombinant
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6.1 Construction by in vivo homologous recombination in 293-Ll cells
6.1.1 Introduction
As noted in the general introduction, one of the major aims of this study was to
construct an Ad5 mutant containing a deletion of the Ll 52/55-kD coding sequences
in order to open space in the viral genome for heterologous genes. In this section I
will describe my attempts to create such a virus by in vivo overlap recombination
methods. The general strategy employed for this purpose is shown in figure 6.1.
Although adenovirus DNA can be manipulated directly, it is generally more
convenient to work on smaller fragments of the genome subcloned into plasmid
vectors. Complete viral DNA can be reconstructed either by ligation of appropriate
cloned and viral genomic fragments, or by overlap recombination in vivo between
such fragments (Chinnadurai et al., 1979).
In this study, deletion of the Ll 52/55-kD coding region was not possible by direct
manipulation of the whole viral genome due to the lack of suitable unique restriction
sites. Thus sub-clones of the viral fragments were created in order to enable the use
of restriction sites unique to each sub-clone which are not unique in the whole viral
genome.
6.1.2 Subcloning of the viral genome right half into a plasmid vector
In order to introduce an Ll 52/55-kD deletion into the right hand Ad5 genome,
plasmid pSaIlC was used in the first step of the extensive cloning experiments.
pSaIlC contains the Ad5 Sall fragment from 9841 bp to 16746 bp cloned into the
SaIl site of pBR322 (figure 6.2). Within this Ad5 SaIl fragment, the Ll 52/55-kD
coding region (Ad5 11050 bp to 12297 bp) is also present and a fragment of 1108 bp
119
(from 11050 bp to 12158 bp) corresponding to the majority of the Ll 52/55-kD
coding region could easily be deleted from the plasmid by digestion with enzymes
Nsil and Apal (figure 6.2). Hence plasmid pSallC-&l was created by the deletion
of an 1108 bp fragment (referred to as Ll deletion or &1 in the rest of the thesis)
from plasmid pSall C (figure 6.2). Later kanamycin-resistance gene from plasmid
pCR II was cloned into pSaI1C-&1 (figure 6.3) in order to make the screening of
recombinants in subsequent cloning steps easier. This new plasmid was called
pSall C-&l-kan.
In the following step, the large SaIl fragment from the plasmid pSallC-&l-kan
containing the Ll deletion within Ad5 sequences 10294 to 16746 bp was cloned into
plasmid pFG that contains the Ad5 right end genome from the SaIl site present at
16746 bp on the Ad5 sequence (figure 6.4) to the right end and was called pAd5RE-
ALI.
6.1.3 Subcloning of the viral genome left half into a plasmid vector
A plasmid harbouring the left half of the Ad5 genome up to the SaIl site located at
16746 bp on the viral genome and containing the Ll 52/55-kD coding region
deletion was constructed in three sequential steps. In the first step, the 9892 bp
fragment of Clal (917 bp) and Nhel (10809 bp) digested Ad5 genome was cloned
into Clal and Nhel digested pBR322 (figure 6.5) to create plasmid pAd5Clal-Nhel.
Plasmid pAd5Clal-Nhel was then used in order to extend the Ad5 sequences
present in the plasmid pXholC which contains Ad5 sequences from the left hand
end to the Xhol site located at 5788 bp on the viral genome (figure 6.6). For this
purpose, both pXholC and pBRAd5Clal-Nhel were digested with EcoRl and AflII
enzymes and the small fragment of pXholC was inserted into the large fragment of
pBRAd5Clal-Nhel (figure 6.6). The new recombinant plasmid was called pAd5LE-
10809.
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AdS left hand genome
Ll deletion
Vx in vivo recombinationin 293-Ll cells
AdS right hand genome
Ll deletion
1
Transfect overlapping DNA into 293-Ll cells. Overlay with semi-solid medium
1
After 8-10 days pick any plaques formed
/ 1
Screen for recombinants by
peR (see section 2.5.4.b).
Infect 293-Ll cells in 60 mm dish.
After 7 days harvest infected cells
and use 0.5 ml to reinfect cells in 90 mm dish.
Freeze and store the remainder.
1
After 4-6 days harvest cells and
screen for recombinats by peR
(see section 2.S.4.a).
Figure 6.1 General Strategy used for the construction and isolation
of Lt S2/SS·kD deleted AdS recombinant.
The diagram lists the stages involved in isolating recombinant adenoviruses
by the methods detailed in chapter 2.
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pBR322 backbone HindUI
pSallC
L152/55/kD
SaIl
Ad 9841 Hind3
Sal!
Ad516746
Nsi1 and Apal digestion
T4 DNApolymerase
Self ligation
(A)
HindU!
I
pSallC-ALl
I I
HindII! Sail
Ad 9841
SaIl
Ad 9841
~Ll Ll
Expected sizes of the fragments
6439 bp upon HindIII digestion (bp)5465 bp
~L1 Ll
3646 bp3646 bp 6439 5465
3646 3646
75 2081
2081 bp 75
(B)
Figure 6.2 Construction of the pSaUC-ALl
(A): Schematic representation; Most of the Ll 52/55-kD coding region in
pSallC was removed by the digestion of the plasmid with Nsil and Apal
followed by treatment with T4 DNA polymerase to create blunt ends and
self ligation of the plasmid.
(B): Restriction digestion analysis of the plasmids pSallC-~Ll and pSallC
by Hindlll that confirms the deletion of the Ll 52/55-kD coding region
present in the plasmid pSallC-~Ll.
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EcoRI Kpnl
pSaI1C-L\L1
10156 bp
Oral pCR II
3947 bp
Hpal Xhol Lld
Hpal&
Xhol digestion Xho1 digestion
Ligation
-c
<1>
E
C)
~-T""
C'CIen
I
Le
"0«
Xhol
,.Sall
pSal1 C-.1L 1-Kan
13191 bp
Figure 6.3 Construction of pSallC-ALl-Kan
The kanamaycin-resistance gene was cloned into pSallC-&l by taking
it out of pCR II using enymes Dral and Xhol and ligating into the Hpal
and Xhol digested pSallC-.1Ll. Note that Hpal and Dral produce
blunt ends and can be ligated without prior manipulation of the DNA.
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Xhol
Ll deletion i«:.... \c-. _ ............ _
.....~ E3
c
Q)
E
Cl
~- pSal1c-al1-Kan
13191 bp
pFG
21402 bp
Sail' \ECORI
digestion
Ligation
E3
Xhol
AdS 1029 pAd5RE-al1
29118 bp
Ll
deletion
Xhol
Figure 6.4 Construction of pAd5RE-aLl
AdS right hand genomic sequences in pFG were extended until the Xhol
site located at 10294 bp on the AdS genome by cloning the large Sail
fragment of pSall C -ALI into the SaIl site of pFG. Recombinant plasmid
was screened by kanamycin and the orientation of the cloned insert was
determined by restriction analysis (data not shown).
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;Z
,-- T pBR322
4363 bps
Cia! &
,Clal
AdS genome (35938 bps)
Nhel
,Nhel ,Nhef,Nhel ,Nhel
917 10809
Clal & Nhel
digestion
CI't._l __.rthel
10809
Ligation
Bam,'i\
pAdScla1-nhe1
14047 bps
Atlll
AdS sequences
from 917 to 10908bps
Figure 6.5 Construction of pAdSc1al-nhel
9892 bps fragment of Clal and Nhel digested Ad5 genome was gel
purified and then cloned into Clal and Nhel digested pBR322 to create
plasmid pAd5cIal-nhel.
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pAd5Cla1-Nhe1
14047 bp
Aflll pXho1C
8088 bp
Xho
AdS
AdS sequences
from 917 to 10908 bp
Afl II digestion
Ligation
pAd5LE10809
14946 bp
Aflll
Figure 6.6 Construction of pAdSLE-I0809
Both pXho1C and pBRAd5Cla1-Nhel were digested with EeoR! and
AflII enzymes and the small fragment of pXho1C was ins rted int
the large fragment of pBRAd5Cla1-Nhe1 in order to extend th AdS
sequences to the Nhe1 site located at 10809 bp on the AdS g nom .
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EcoRI BamHl
Sail
d516746
pAd5LE10809
14946 bp
Aflll pSal1 C-l1L 1
10156 bp
Nhel Ll deletion
AdS 10809
Aft II digestion
Ligation
Sail
BamHI
Sail
AdS 16746 pLE-l1L 1
19901 bp
Figure 6.7 Construction of pLE-l1Ll
Large fragment of Nhe1 and BamH1 digested pSall -Ll (contain
an L1 52/55-kD deletion in the Ad5 sequences) was cloned into
pAdSLE-10809 digested by the same enzymes extending the 1 ft nd
Ad5 sequences up to the Sal l site located at 16746 bp on the viral g n m .
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In the last step, the large fragment of Nhel and BamHl digested pSaIlC-L\Ll
(contains an Ll 52/55-kD deletion in the Ad5 sequences) was cloned into pAd5LE-
10809 digested by the same enzymes (Figure 6.7) extending the left hand Ad5
sequences up to the SaIl site located at 16746 bp on the viral genome. This plasmid
was then called pAd5LE-L\L1.
6.1.4 in vivo overlap recombination experiments
Having constructed the two plasmids, one harbouring the left end part of the Ad5
genomic DNA and the other the right end part of the Ad5 genomic DNA (pAd5LE-
L\Ll and pAd5RE-L\Ll respectively), the next step was to try to reconstitute a virus
genome from them in vivo by overlap recombination after transfecting 293-Ll cells
with linearized forms of both of the plasmids. Since both the pAd5LE-L\Ll and
pAd5RE-L\Ll carry the Ll 52/55-kD coding region deletion at the appropriate
location in region where the Ad5 genomic sequences in the plasmids overlap each
other and since the naked adenovirus genomic DNA is infectious, any viral DNA
reconstituted due to an overlap recombination event inside the transfected 293-Ll
cell nucleus would be expected to be infectious, leading to the replication of the
reconstituted Ll 52/SS-kD deleted viral DNA and thus production of new mutant
viral particles.
Overlap recombination experiments involved the transfection of 293-Ll cells with
three different combinations of molecules (Figure 6.8). The first combination
contained linearized plasmids pAdSLE-L\Ll with pAdSRE-L\Ll (digested with EcoR
I and CIa I respectively), the second combination contained linearized pAdSLE-L\Ll
with the 24315 bp fragment (corresponding to right end of the viral genome) of
Nsil-digested wt Ad5 DNA and the third combination contained linearized pAd5RE-
L\Ll with the 11311 bp fragment (corresponding to left end of the viral genome) of
MluI-digested wt Ad5 DNA. The sizes of the overlapping regions in each
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L letion Sail
AdS left hand genome 16746
5
XEcoRI in vivo recombination EcoR I Cia I I)0 Cia I in 293-L1 cells 35938
plasmid backbone Xho I
10294 Ll deletion
AdS right hand genome 3'
letion Sail
AdS left hand genome 6746 olasmid backbone5~1--------~-----------------+------~--~~~~~
EctI X
L
in vivo recombination EcoR I
in 293-L1 cells II)
Nsi I
11623
AdS right hand genome 3'
35938
Mlul
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plasmid backbone Xho I
10294 Ll deletion
in vivo recombination
in 293-L1 cells
Cia I III)
35938
CIa I
AdS right hand genome 3'
1
IV)5' ~-----------------------------3'
Ll deletion
Figure 6.8 Three different combinations of molecules used in overlap
recombination experiments.
I) linearized plasmids pAd5LE-LI with pAd5RE-LI
(digested with EcoRI and Cia! respectively); II) linearized pAd5LE-Ll with the
24315 bp fragment (corresponding to right end of the viral genome) of NsiI-
digested wt Ad5 DNA and ;111)linearized pAd5RE-LI with the 11311 bp
fragment (corresponding to left end of the viral genome) of Mlul-digested wI
Ad5 DNA. IV) Any recombination event occurring between the molecules in
each combination gives rise to infectious viral DNA lacking the Ll 52/55-kD
coding region.
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of molecules were 5344 bp, 4588 bp and 1017 bp respectively and any
recombination event occurring between the molecules in each combination giving
rise to infectious viral DNA would be expected to carry a deletion of the Ll 52/55-
kD coding region (Figure 6.8). The experiments were carried out as follows: 5 Ilg of
each DNA molecule were used for transfection of 293-Ll cells in 60 mm dishes by
lipofection (see Chapter 2) and the dishes were overlaid with semi-solid medium (as
it was done in plaque assay experiments, see chapter 2). After 8-10 days of
incubation any plaques formed were picked and the agar plugs were resuspended in
I ml of DMEM-1O% FCS; 370 III of each suspension were used for the detection of
recombinants by PCR (see Section 2.5.4.b). The remaining 630 III of each plaque
suspension were used to infect 293-Ll cells in 60 mm dishes and the infected cells
were harvested after four days and lysed by three freeze and thaw cycles. 0.5 ml
from each cell harvest was then used for another round of infection of 293-Ll cells
in 90 mm dishes and the remaining lysates were stored at -70°C. After 4-6 days of
incubation, the infected cells were harvested and screened by PCR for the
recombinants. To detect recombinants by PCR, primers L5 and L6 were designed:
These primers hybridise to sequences flanking the Ll 52/55-kD coding region
(Figure 6.9) and amplify a fragment of 194 bp from Ad5 sequences containing a
deletion of the Ll 52/55-kD region and a fragment of 1302 bp from Ad5 sequences
containing an intact Ll 52/55-kD coding region.
In all the experiments carried out on cells transfected with the combination of
linearized plasmids pAd5LE-LlLI with pAd5RE-LlLI no clearly identifiable plaques
were observed. Any morphological formations which resembled that of plaque
formation were treated as if they were plaques and subjected to at least 3 rounds of
plaque amplification and peR analysis, however there was no amplification of a
diagnostic fragment in any of them. On the other hand, in control experiments where
purified 24315 bp fragment (corresponding to the right end of the viral genome) of
Nsil-digested wt Ad5 DNA and 11311 bp fragment (corresponding to the left end of
130
the viral genome) of Mlul-digested wt AdS DNA were used for the transfection of
293-Ll or 293 cells, a 1302 bp peR fragment corresponding to amplification from
wt viral DNA was consistently identified from material in any of the formed
plaques.
In contrast to the result with fragment combination I (figure 6.8), plaques were
regularly observed and amplified from cells transfected with fragment combinations
II and III (figure 6.8). However, in all of the plaques amplified and analysed by
peR, a fragment of around 1300 bp corresponding to an intact Ll S2/SS-kO region
was detected. This meant that the plaques were formed by a wild type virus in each
case and this was most probably due to the presence of incompletely digested wild
type AdS DNA in the transfection mixture.
The same results were obtained after several repetitions of these experiments
suggesting two possibilities; 1. the expected overlap recombination could be
occuring at a very low frequency such that it would require much higher numbers of
repetitions of the transfection experiments to be detected. Although in the control
experiments, where purified 24315 bp fragment (corresponding to right end of the
viral genome) of Nsil-digested wt AdS DNA and 11311 bp fragment (corresponding
to left end of the viral genome) of Mlul-digested wt AdS DNA were used for the
transfection, all the plaques screened contained wild type AdS, it is possible that it
was due to incomplete digested viral DNA during the preparation of the relevant
virus genome fragments rather than reconstitution of the viral genome due to overlap
recombination. 2. Another possibility is that an AdS virus deficient in Ll S2/SS-kD
coding sequences can be replication incompetent due to the reason mentioned above.
Although 293-Ll cells were shown to complement the missing Ll S2/55-kD protein
function in AdS Ll mutants ts369 and HSpm8001 (see section 5.3), this does not
necessarily mean that these cells would also be able to complement the same
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missing protein function of a reconstituted Ad5 genomic DNA containing a deletion
of the Ll 52/55-kD coding sequences. Those sequences may well be carrying one or
more yet undiscovered cis-acting elements having functions that are important
directly or indirectly for the replication of the virus, rendering construction of such a
virus impossible.
6.2 Construction in E. coli
6.2.1 Attempts to clone the entire AdS genome containing a deletion of the Ll
S2/SS-kD into a bacterial plasmid.
Since the failure to construct an Ll 52/55-kD-deleted Ad5 by overlap recombination
in 293-Ll cells could be due to very low frequencies of the expected recombination
event, one way to test such a theory would be to attempt to construct the virus by
transfecting 293-Ll cells with a plasmid containing the entire Ad5 sequences except
the Ll 52/55-kD coding sequences. Such an experiment would also prove whether
or not the deleted Ll 52/55-kD coding sequences harbours any cis-acting sequences
required directly or indirectly for the replication of the virus.
One way to construct such a plasmid containing the entire Ad5 sequences except the
Ll 52/55-kD coding sequences was to take out the Ad5 sequences present in the
plasmid pAd5LE-ALI and insert them into an appropriate site in pAd5RE-AL1, as
shown in figure 6.11. In this way, a plasmid containing the entire Ad5 genome could
be amplified in bacteria and then transfected into 293-Ll cells after being purified
and linearised. Since there is no need for a recombination event in order to
reconstitute a viral genome, the probability of isolating an Ll 52/55-kD deleted
mutant Ad5 would be much higher. In order to achieve this, the tetracycline-
resistance gene from pBR322 was first cloned into pAd5LE-ALl to ease the
selection of recombinant plasmids in subsequent cloning steps (Figure 6.10). The
next step consisted of taking out the tetracycline resistance gene and Ad5 left end
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(i) (ii)
----7
L5
N il/Apa1
h
Nsil
I
Apal
PCR amplification
(A)
194 bp
c=J
1302 bp
M mock AdS RE LE AdS-DNA
(B)
1000 1302 bp
Figure 6.9 Primers used for the detection of Ll S2lSS-kDdeleted recombinants
(A) Primers and their direction of hybridization are shown by an·ows. (i) and (ii) how
the amplification of fragrrents from wild type and Ll 52J55-kD deleted AdS equ n
respectively.
(B) PCR amplification by primers L5 and 1.6 from different templates to t t th r Liability
of the detection rrethod. M: molecular size markers; mock: DNA extract from mock-inf t d
293-Ll cells; AdS: DNA extract from AdS-infected 293-Ll cells; RE: plasmid pAdSRE- 1;
LE: plasmid pAdSLE- &1; AdS-DNA: purified AdS genomic DNA
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EcoRI
Ad5
left end
Sail
Ad516746
XmnI
pLE-AL1
19901 bp DraDral
EcoI&
DraI digestion
Ligation
Pmel
pLE-AL 1-tet
16686 bp
Figure 6.10 Construction of pLE-AL1-tet
The large fragment of XmnI and EcoR! digested pLE-ALI (contains
an Ll 52/55-kD deletion in the Ad5 sequences) was ligated to the large
fragment of DraI and EeoR! digested pBR322.
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pLE-AL t-tet
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pAd5RE-A L1
29118 bp
PmeI&
Bst l107I (BstZl7I)
digestion
PmeI&
Ligation
E3
pAd5-amp-tet
37481 bp Ll 52/55-kD
deletion
Figure 6.11 Attempted construction of pAdS-amp-tet
Large fragment of Xmn I and pMe I digested pLE-AL1-tet was tried to be
inserted into the large fragment of Pme I and Bst1107 I digested pAd5RE-ALl.
Plasmid pAd5-amp-tet could then be isolated by ampicillin and tetracyclin
selection and the orentation could be determined by restriction dige tion analy i
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genome from plasmid pLE-L\Ll-tet by the enzymes XmnI and PmeI (both produce
blunt ends) and cloning the fragment into pAd5RE-lll digested by Bstl107I and
PmeI (both produce blunt ends), reconstituting the entire Ad5 genome with a
deletion of the Ll 52/55-kD coding region (Figure 6.11). Once created, the entire
Ad5 sequences then could be taken out from this plasmid by CIa I digestion (note
that the CIa I site present towards the left end of the viral genome is protected by
dam methylase in E. coli) and used for the transfection of 293-Ll cells. However all
the attempts to construct pAd5-amp-tet failed, possibly due to instability of such a
large plasmid or to the poor efficiency of ligation of the two large blunt ended
fragments.
6.2.2 Attempts to construct by homologous recombination in E. coli
Having failed in both in vivo overlap recombination in 293-Ll cells and construction
of a plasmid harbouring the entire manipulated AdS sequences, a different strategy
was planned. This strategy was based again on overlap recombination for the
reconstitution of an infectious viral genome but this time in E. coli rather than 293-
Ll cells. For this purpose a Lactococcus lactis plasmid vector, pIL2S3, which does
not replicate in gram-negative bacteria including E. coli, was used. This plasmid
contains a lactococcal origin of replication, a multiple cloning site and an
erythromycin-resistance gene which can be used for selection in both L lactis and E.
coli strains. AdS left end genome from the plasmid pAd5LE-10809 was cloned into
pIL253 in L. lactis (Figure 6.12). The new plasmid was called pIL-LE and used for
the transformation of the E. coli strain MC 1061 harbouring the plasmid pAd5RE-
ALI. The purpose of this experiment was to reconstitute the AdS viral genome
containing a deletion of the Ll S2/55-kD coding region in E. coli by an overlap
recombination event between the plasmids pIL-LE and pAdSRE-L\Ll (Figure 6.13).
Such an overlap recombination would lead to the formation of single large plasmid
termed pIL-AdS. Since pIL-LE, which contains an erythromycin-resistance gene, is
incapable of replicating in E. coli, any colonies grown on a selective agar medium
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Figure 6.12 Construction of pIL-LE
A fragment containing the AdS sequences from pAd5LB-I0809 was taken ut by
enzymes BcoR I and Nhe I and cloned into the lactococcal pia mid pIL253
which was digested with Xba I and BeoR 1. Note that Nhe I and Xba I pr du
compatible cohesive end that can be ligated to each other without and f r
further manipulation of the ends.
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Figure 6.13 Attempts to reconstitute AdS genomic DNA by overlap
recombination in E. coli.
E. coli strain MC 1061 harbouring the plasmid pAd5RE-LlL 1 was tran form d
with the plasmid pIL-LE which acts as a suicide vector in E. coli due to its inability
to replicate in gram-negative bacteria. Upon selection of the transformed ba t ria
with erythromycin, colonies containing the plasmid pIL-Ad5, which would b form d
by an overlap recombination between the pJasmids pIL-LE and pAd5RE-b.Ll, uld
be picked.
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containing erythromycin would be expected to harbour recombinant plasmid pIL-
Ad5 in which the entire Ad5 genomic sequence containing a deletion of the LI
52/55-kD coding region would reside. This plasmid could then be purified,
linearized by using CIaI, and used for the transfection of 293-LI cells in an attempt
to make an LI 52/55-kD deleted Ad5 virus.
However, although several erythromycin-resistant colonies of E. coli were isolated,
restriction analysis of the plasmid preparations from these colonies revealed that
they all contained the plasmid pAd5RE-M.I rather than the expected pIL-Ad5. The
experiment was repeated several times but same results were obtained consistently,
suggesting that the erythromycin-resistant colonies were possibly either due to the
integration of the plasmid pIL-LE into the bacterial genome or to the selection of
erythromycin escape mutants of E. coli. The underlying reason for not being able to
isolate a colony containing the expected plasmid pIL-Ad5 could the plasmid's
instability because of its large size (around 44000 bp).
6.3 Summary
This chapter describes attempts to make an adenovirus type 5 recombinant lacking
1108 bp of the 1247 bp LI 52/55-kD coding region. Failure to make such a virus
described in section 6.1 could be due to the sequences missing in the deletion of the
LI 52/55-kD coding region having other functions such as to destroy the viability of
the intended deleted virus, even in the presence of effective LI 52/55-kD
complementation. Since it is not possible to distinguish between this hypothesis and
the alternative of failure to create the required recombinant genome by the
traditional overlap recombination experiments in mammalian cell lines, a better
approach would be to reconstitute the entire viral genome in a single plasmid prior
to the transfection of the cell lines. By this way the construction of the desired viral
genomic sequences would not depend on a low frequency recombination event. In
section 6.2, attempts to construct the viral genome in a single bacterial plasmid prior
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to the transfection of the cell lines by using two different strategies were described
and possible reasons for the failure of those attempts were explained.
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Chapter 7
Investigation of the effects of
adenovirus 5 Ll-52/55 kD protein on
major late promoter (MLP) activity
141
7.1 Introduction
The adenovirus Ll 52/55-kD protein is expressed both in the early and late stages of
infection, raising the possibility that it has multiple roles in the viral life cycle. Two
temporal classes of mRNAs, early and late, are produced during adenovirus
infection. The late transcripts are further divided into five families of 3' coterminal
transcripts, Ll to L5 (Fraser and Ziff, 1978). The Ll transcripts encode the lIla and
52/55-kD proteins. Unlike the other families of late transcripts, the Ll mRNAs are
detectable very early after infection has commenced (Akusjarvi and Persson, 1981;
Nevins and Wilson, 1981) and the 52/55-kD protein is detectable 6 or 7 hours
postinfection (Lucher et al., 1986). Analysis of the 52155-kD protein indicates that it
is required for the encapsidation of the viral genome during packaging (Gustin and
Imperiale, 1998) and also it has been shown that the Ll 52/55-kD protein interacts
specifically with adenovirus IVa2 protein (Gustin et al., 1996). The early appearance
of the 52/55-kD protein makes it unique among the gene products expressed from
the adenovirus major late promoter (MLP) and its interaction with the IVa2 protein
suggests that the 52/55-kD protein may have functions in addition to those involved
in encapsidation of viral DNA (Gustin and Imperiale, 1998).
The IVa2 protein has been shown to be a late-stage-specific transcriptional activator
of the MLP (Tribouley et al., 1994). It is a component of two complexes, DEF-A
and DEF-B, that bind to and activate the MLP (Tribouley et al., 1994; Lutz and
Kedinger, 1996) (Figure 7.1 a). DEF-B consists of a homodimer of the IVa2 protein.
The DEF-A complex has been partially purified and shown to be composed of IVa2
associated with a viral or virally induced factor (Lutz and Kedinger, 1996). It is
conceivable therefore that the Ll 52/55-kD protein associates with the IVa2 protein
to form the DEF-A complex. A 40 kD peptide present in infected cells has been
shown to co-purify with the DEF-A complex (Lutz and Kedinger, 1996). Previous
immunoblot analysis of the 52/55-kD protein has indicated that there is major band
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at 40 kD that presumably arises from the action of the viral protease at a consensus
cleveage site (Hasson et al., 1992). It is possible that this cleavage product is the
functional partner of IVa2 in the DEF-A complex.
7.2 Results
With the precedent of IVa2 studies in mind, which revealed the contribution of this
intermediate gene product in MLP activation (Lutz and Kedinger, 1996), I examined
the effect of Ll 52/55-kD expression on MLP activity.
In order to confirm the interaction of the Ll 52/55-kD protein and the IVa2protein in
vivo, radiolabelled extracts from cell lines 293-Ll and 293-LI-IVa2 were
immunoprecipitated by using anti-Ll, anti-Ll pre-immune, anti-IVa2, and anti-IVa2
pre-immune polyclonal antisera. Figure 7.2 represents the co-immunoprecipitation
of Ll 52/55-kD and IVa2 proteins by both anti-Ll and anti IVa2 polyclonal
antibodies and supports the finding by Gustin et al., 1996. In addition, this result
also shows that Ll 52/55-kD and IVa2 proteins interact in the absence of infection,
confirming that no other viral proteins are required for their interaction.
The experimental strategy employed for the investigation of the effects of Ll 52/55-
kD protein on MLP involved the transfection of COS cells with plasmids pMLP-
CAT (Lutz et al., 1997), a reporter plasmid which contains chloramphenicol
acetyl transferase (CAT) as the reporter gene inserted down-stream of the Ad5 wild-
type MLP sequence (-246 to +131, with respect to the MLP start site) (Figure 7.1
b), and one or more of the plasmids pCDNA3.1lHisB/lacZ, pMEP-CMV-LI and
pREP9-IVa2. Plasrnids pMEP-CMV-LI and pMEP-CMV-IVa2 express Ad5 genes
Ll 52/55-kD and IVa2 genes respectively (see Chapter 5), and pCDNA3.1IHisB/lacZ
expresses the LacZ gene from the CMV promoter. Initial attempts to study the
effects of Ll 52/55-kD protein on MLP activity involved the transfection of Ad5 or
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mock-infected 293-Ll, 293-IVa2 (Brey, 1999), and 293-Ll-IVa2 cells with the
reporter plasmid pMLP-CAT but it was failed to get detectable levels of CAT
expression from the reporter plasmid in any of the transfected samples (data not
shown). Therefore it was decided to switch to the system employed by Lutz et al
(1997) in which the COSl cells are transfected with the reporter plasmid and other
constructs which express the relevant proteins. Thirty-six hours after transfection,
the cells were harvested, extracts were prepared and aliquots, normalised by protein
concentration and beta-galactosidase activity, were assayed by CAT-ELISA (see
Chapter 2) to determine the level of CAT expression. The relative MLP activities of
the samples were calculated as shown and described in Table 7.1.
Initially, control experiments were performed, employing pIX expression vector
pREP9-IX together with the pMLP-CAT and pCDNA3.llHisBflacZ plasmids for the
transfection of COS 1 cells in order to control the reliability of the method by
comparing the results with those obtained by Lutz et al. (1997). According to their
finding, the expression of the product of the adenovirus gene IX stimulated
adenovirus MLP in a dose-dependent fashion, independent of other viral proteins.
5 Jlg of pMLP-CAT, 1 ug of pCDNA3.llHisBflacZ and 500 ng of pREP9-IX or
control pREP9 plasmids were used for the transfection of 60 mm dish COS 1 cell
cultures. In each transfection, the final amount of pREP9 vector sequences was
adjusted to 500 ng by addition of empty pREP9. Figure 7.3 shows the mean values
(with the standard deviation, SD) of four independent MLP activity experiments in
COS1 cells transfected with either pREP9-IX or empty vector pREP9. The
experiment showed 2.4-fold increased MLP activity in the cells that received pIX
expressing vector pREP9-IX, in agreement with the results published by Lutz et al.
(1997). Also, in another experiment, the effects of different concentrations of pIX on
MLP activation were investigated. The result of this experiment is shown in Figure
7.4. A dose-dependent increase MLP activation up to an input of 100 ng pREP9-1X
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6000 bp
I
5' gtgttcctga aggggggc~aaggggg tgggggcgcg ttcgtcctca Cj.CtcttCCg
:MLPTATA box MLP start
catcgctgtc tgcgagggcc agctgttggg gtgagtactc cctctgaaaa gcgggcatga
cttctgcgct aagaitgtca gtttdcaaaa acgaggagga Ittgatllttc acctggcccg c 3'
DEl DE2b DE2a I
(DEF-A) (DEF-B) (DEF-A) 6177 bp
(A)
Amp pMLP·CAT
4650 bp
intron sequences
SV40 polyA
(B)
Figure 7.1 The AdSMLP and the reporter plasmid pMLP·CAT (Lutz et
aI., 1997)
(A) The sequence of the MLP region and minimal targets (DEI, DE2a and
DE2b) for the DEF-A and DEF-B binding activities, which activate MLP at lat
times. (B) Map of plasmid pMLP-CAT. Plasmid contains SV40 p lyad nylati n
signals, the cat gene, the SV40 small t intron sequences, the ampicillin-
resistance gene, and the Ad5 MLP.
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Figure 7.2 Co-immunoprecipitation of Ll 52/55-kD and IVa2 proteins
from 293-Ll- IVa2 cells
Proteins from extracts of radiolabelled 293-Ll and 293-L1- IVa2 cells were
immunoprecipitated by using polyclonal anti-sera, or matched control pre-
immune sera, against Ll 52/55-kD or IVa2 proteins as indicated. Samples
were analysed on a 15 % SDS polyacrylamide gel and detected by autoradiography.
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pMEP-CMV or pREP9) were used for the transfection f 0 mm di h I II ultur
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experiments.
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per plate was observed, which again correlates with the published data.
Reproduction of the previously published data published by Lutz et al. (1997) gave a
good indication of the reliability of the method employed for the investigation of the
effects of other AdS late proteins on the adenovirus MLP activity. The next step was
to investigate the effects of AdS N a2,L! 52/S5-kD and both IVa2 and L1 52/55-kD
proteins on the adenovirus MLP activity. For this, COS! cells in 60 mm dishes were
transfected with S J.1gof pMLP-CAT, 1 J.1gof pCDNA3.1IHisB/lacZ and 100 ng of
pMEP-CMV -L1 or pMEP-CMV -IVa2or both. In each transfection the the amount of
pMEP-CMV vector sequences was adjusted to 500 ng by the addition of empty
pMEP-CMV (in case of control transfections involving Ad5 infection, the cells were
infected with wild type Ad5 12 hour after transfection). Thirty-six hours after
transfection, the cells were harvested, extracts were prepared and aliquots,
normalised by protein concentration and beta-galactosidase activity, were assayed
by CAT -ELISA for the determination of CAT protein concentration. The mean
values from the results from four independent experiments, and their standard
deviations are shown in a graphical form in figure 7.S. As it can be seen in the
figure, neither the L! 52/55-kD nor the IVa2 protein alone had any effect on the
reporter activity, as would be expected if both proteins are needed to form the DEF
A complex which binds to MLP to cause its activation together with the DEF B
complex. However, the expression of both proteins at the same time in the same
cells also had no effect on the MLP, disproving the idea that the L1 52/S5-kD
protein is involved with IVa2, in the activation of MLP. In the control experiments
where the transfected cells were infected with wild type AdS, there was marked
increase in the CAT reporter activity as expected due to the presence of viral or
virally induced factors in the cells. Also in cells transfected with the pIX expression
plasmid as a positive control there was increased reporter activity in agreement with
earlier observations.
1S2
7.3 Summary and Discussion.
In this chapter I have described an investigation of the effects of the Ad5 L1 52/55-
kD protein on Ad5 MLP activity by transfection of COS1 cells using a MLP driven
CAT reporter construct.
The early appearance of the 52/55-kD protein has been taken as an indication that it
might have additional functions at early times during infection (Hasson et al., 1989).
Also, previous publications had led to the hypothesis that this L1 protein might
activate MLP in a complex with IVa2 protein (Gustin et al., 1996). However,
according to a recently published article by Gustin and Imperiale, (1998) their
analysis of infection by an adenovirus harbouring a mutation that blocks expression
of the L1 52/55-kD protein, H5pm8001, did not reveal a requirement for the 52/55-
kD at early times. As they determined by examining the onset of DNA replication
and gene expression, H5pm8001-infected 293 cells made the transition from the
early to late stage infection at the same time as did wild type Ad5 infected cells and
the 52/55-kD protein was not required for the activation of the MLP during
infection. The results of the transient expression experiments in COS cells presented
in this chapter also support the idea that L1 52/55-kD protein does not have any
effects on the activation of the MLP. The infected cell-specific partner protein with
IVa2 in the MLP-activating factor DEF-A therefore remains unidentified.
Thus it would be appropriate to speculate that, the interaction between the IVa2 and
52/55-kD proteins is involved in another function, possibly in the packaging of the
viral genome since the 52/55-kD protein mediates encapsidation of the viral genome
(Gustin and Imperiale, 1998).
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Chapter 8
General discussion
(
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The enabling technology of gene therapy is based on strategies for delivering genes.
To do this, gene delivery vehicles called vectors have been developed, which
encapsulate therapeutic genes for delivery to cells. Many of the vectors currently in
use are based on attenuated or modified versions of viruses. Over billions of years of
evolution, viruses have developed extraordinarily efficient ways of targeting cells
and delivering their genomes into the cells, which unfortunately leads to disease.
The challenge in developing such viruses as vectors is to remove the disease-causing
components of the virus and insert recombinant genes whose expression will be
therapeutic to the patient. The modified viruses cannot be allowed to replicate in the
patient, but must retain the ability to efficiently deliver genetic material.
Of the numerous viral vectors investigated, those based on adenoviruses have
proved efficient for gene transfer both in vivo and in vitro. They are relatively safe
and the extensive knowledge of their biology has made them strong candidates for
use in gene therapy applications. Despite their advantages, the lack of long-term
persistence of gene expression from cells transduced with these vectors, the
generation of host immune responses against them, and the limited insert-carrying
capacity of these vectors has greatly limited their application.
The aim of the work presented here was to achieve improvements over currently
existing adenovirus vectors for gene therapy through increasing their insert carrying
capacity by the deletion of some of the viral late gene(s). Attention was focused
primarily on the Ll 52/55-kD protein-coding region. The effect of this gene product
(Ll 52/55-kD protein) on the expression of other late genes was also investigated.
In the preceding chapters I have described experiments designed to construct
complementing cell lines that would support the growth of adenoviral vectors
containing deletions in their Ll 52/55-kD, Ll 52/55-kD and IVa2, and Ll 52/55-kD
and IX coding regions. Both IX and IVa2proteins have functions that are involved in
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the transactivation of the adenovirus MLP, hence the production of other viral late
proteins. Initially, Ll 52/55-kD protein was also believed to be involved in the
transactivation of the viral MLP. Thus the construction of recombinant adenoviral
vectors containing deletions in their Ll 52/55-kD, Ll 52/55-kD and IVa2, and Ll
52/55-kD and IX coding regions together with the deletions available in currently
used vectors was expected to result not only in increased insert capacity but also to
decreased immunogenicity due to decreased levels of viral late gene expression.
Initial experiments described in Chapters 3-5 involved the cloning and sequencing of
the Ad5 Ll 52/55-kD cDNA and production of antibodies against Ll 52/55-kD
protein. The antibodies were later used for the detection of the Ll 52/55-kD protein
from 293-Ll cells. 293-Ll cells were constructed by transfection of a stably
maintained episomal mammalian expression vector harboring the Ll 52/55-kD
expression cassette. Similarly, cell lines 293-LI-IVa2 and 293-LI-IX expressing the
Ll 52/55-kD and IVa2 and Ll 52/55-kD and IX proteins respectively were
constructed using appropriate episomal expression vectors.
In Chapter 6, attempts to construct an adenovirus recombinant deficient in Ll 52/55-
kD coding region were described. Although various different strategies were
employed for the construction, isolation of such a recombinant proved more difficult
than anticipated, and ultimately no such virus was isolated. One possible explanation
for the failure to isolate such a virus could be due to the nature of sequences missing
in the deleted Ll 52/55-kD coding region. Adenovirus gene expression is complex
(see Chapter 1) and the sequences may well be carrying one or more yet
undiscovered cis-acting elements which have functions that are important directly or
indirectly for the replication of the virus, rendering construction of such a virus
impossible. It is also possible that, during the cloning steps described in chapter 6, a
mutation or mutations might have been introduced into the viral sequences
elsewhere in the genome destroying the infectivity of the recombinant viral genome.
156
These reasons are largely the subject of speculation, and require experimental
evaluation. One way of doing this would be the construction of both the wild type
and recombinant viral sequences in separate single plasmids before transfection of
the cell lines in an attempt to make the virus. This way it would be possible to test
the presence of any mutations in the cloned viral sequences that would affect the
infectivity of the viral genome. The advantages this system would provide are firstly
there is no need for a recombination event in order to reconstitute a viral genome in
vivo and secondly, ease of production of large amounts of the recombinant viral
genome DNA. However, several attempts to carry out this experiment failed and
consequently, the work had to be abandoned due to the time limitations.
Had the work described in Chapter 6 resulted in the isolation of an Ll 52/55-kD
deleted virus, insertion of IVa2 and/or IX coding region deletions into the Ll 52/55-
kD deleted viral genome would have been attempted. The ultimate target would be
to create a recombinant adenovirus with deletions of El, E4, Ll 52/55-kD, IVa2, and
IX coding regions, and containing a reporter (e.g. f3-gal) expression cassette. The
duration of reporter gene expression and the nature and extent of the immune
response to the vector in mice would be compared to those produced by a
recombinant adenovirus containing the same reporter cassette and the deletions of
El and E4 region only and the possible advantages or disadvantages of using such a
vector would therefore be assessed.
Experiments described in Chapter 7 were done in order to investigate the effects of
LI 52/55-kD on the adenovirus MLP. Early reports suggested that a possible role for
the 52/55-kD protein might be to regulate proper temporal activation of late gene
expression by interacting with the IVa2 protein, since IVa2 was known to be involved
in this process by interacting with another yet unknown viral or infection-induced
protein. However transient expression experiments carried out by transfection of
COS cells with a MLP dependent reporter gene (CAT) and expression vectors for Ll
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52/55-kD and/or IVa2 did not reveal any role for the Ll 52/55-kD protein in the
activation of MLP. Therefore, since the Ll 52/55-kD protein is known to be
involved in the process of viral genome encapsidation, it can be speculated that the
interaction between IVa2 and the Ll 52/55-kD proteins is involved in packaging the
viral genome. Experiments designed to examine if these proteins, alone or in
combination, have any affinity for the adenovirus packaging signal would be an
appropriate investigation of this speculation.
The basic challenge in gene therapy is to develop approaches for delivering genetic
material to the appropriate cells of the patient in a way that is specific, efficient and
safe. This problem of "drug delivery," where the gene is a drug, is particularly
challenging for genes which are large and complex and require targeting to the
nuclei of cells. However, if genes are appropriately delivered they can persist for the
life of the cell and potentially lead to a cure. For gene therapy to become a widely
used medical therapy, several technical hurdles need to be overcome. First, gene
transfer vectors are needed that can be injected directly into the patient. In addition
the injected vector would need to target specifically to and enter a particular tissue
or organ. Second, once the gene vector has reached the cell of interest, its genetic
content needs to integrate safely into a non-critical site on the chromosome,
homologously recombine with the defective gene it is trying to replace or otherwise
achieve long-term persistence. Finally, ways must be found to control adverse
immune response to vector and trans gene products.
Further developments of adenovirus vectors, of the type described and attempted in
this thesis represent a likely avenue through which some or all of these obstacles
may be overcome.
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Appendix A : Primers
API:
5' TIT TTOOATCCATOCATCCOOTOCTOC 00 3'
AP2:
5' TTTTIOAATTCCOCTTAOTACTCOCCOTCCT 3'
L5:
5' OOAAACAOOOACOAOCC 3'
L6:
5' TOATCAOAAACATCACCOOC 3'
Reverse primer:
5' CAOOAAACAOCTATOAC 3'
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Appendix B: Buffers and Solutions
1% (w/v) bactotryptone, 1% (w/v) NaCI, 0.5 % yeast extract
1 % (w/v) bactotryptone, 1 % (w/v) NaCI, 0.5 % yeast extract, 1.5
% (w/v) bacto-agar
137 mM NaCl, 2.7 mM Na2HP04, 1.4 mM KH2P04
89 mM Tris-HCI, 89 mM boric acid, 1 mM EDT A pH 8.0
25 mM Tris-HCI, pH 7.5, 137 mM NaCl, 5 mM KCI, 0.7 mM
Na2HP04
TE 10mM Tris-HCI, pH 8.0, 1 mM EDT A
LB
LB agar
PBS
TBE
TD
TNE 10mM Tris-HCI, pH 8.0, 100 mM NaCI, 1mM EDT A pH 8.0
TS 25 mM Tris base, 137 mM NaCI, 5 mM KCI, 0.7 mM Na2HP04,
0.9 mM CaCh, 1 mM MgCh
lOX DNA gel 0.21 % Bromophenol Blue, 0.21 % Xylene Cyanol FF, 0.2 M
loading buffer EDT A, pH 8.0 and 50 % Glycerol
Antibiotic and X-gal stock solutions
Antibiotic Stock Solutions Cone Working Concentration
Ampicillin 50 mg/ml in H2O 100 ug/ml
Chloramphenicol 34 mg/ml in ethanol 170 ug/ml
50 mg/ml in athanol
500 ug/ml for E. coli
Erythromycin
5 ug/ml for L. lactis
Kanamycin 10 mg/ml in H2O 50 ug/ml
Streptomycin 10 mg/ml in H2O 50 ug/ml
Tetracycline HCI 5 mg/ml in ethanol 50 ug/ml
X-gal 40 mg/ml in dimethyl formamide 500 ug/ml
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Appendix C: Suppliers
All chemicals, of analytical or molecular biology grade, were supplied by BDH
(Poole, Dorset, UK), Sigma (Poole, Dorset, UK) or Fisons Scientific
(Loughborough, UK) unless otherwise stated below.
Amersham (Amersham, Bucks, UK)
Biotinylated goat anti-rabbit polyclonal antibody, streptavidin-biotinylated
horseradish peroxidase, Hybond C membrane, SDS-PAGE rainbow markers, T7
Sequenase (version 2.0) DNA polymerase
Becton Dickinson (Cockeysville, USA)
Yeast extract
BioRad (Hemel Hempsted, Herts, UK)
Acrylamide, N,N' -methylene-bis-acrylamide, TEMED, ammonium persulphate
BOC (Surrey, UK)
N2, C02, dry ice
Boehringer Mannheim (Lewes, East Sussex, UK)
Hygromycin B, ClAP
Difco Laboratories (Basingstoke, UK)
Bacto-agar, bactotryptone, M17, noble agar
Fisher Scientific (Loughborough, UK)
Chloroform, ether, caesium chloride, SDS
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Gibco BRL (Renfrewshire. UK)
DMEM, dsDNA markers, FCS, G418, Klenow DNA polymerase, Lipofectace, NCS,
Restriction enzymes and buffers, T4 DNA ligase, T4 DNA polymerase, Taq
polymerase, trypsin, versene
Invitrogen (Carlsbad. USA)
Mammalian expression vectors
Kodak (London. UK)
X-ray developing and fixation solutions, X-ray film
New England Biolabs (Herts. UK)
Restriction enzymes
Pharmacia Biotech (Herts. UK)
dNTPs, glutathione-Sepharose 4B beads, pGEX-2T
Oiagen (Hilden. Germany)
Qiaprep plasmid mini prep and maxi prep kits
Stratagene (Cambridge. UK)
E. coli XLI Blue, E. coli XLI Blue MR
University of Warwick media preparation service
PBS, dH20, trypsin/versene, neutral red
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